[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 44639
1. Jia KD, Zou ZY, Lv DY: The Value of Survivin Gene and Proliferation of Hepatocytes in Screening for Hepatocellular Carcinoma. Gastroenterology Res; 2009 Dec;2(6):333-337
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prospective surveillance programs on patients with liver diseases based on repeat ultrasound examinations of liver and serum α-fetoprotein (AFP) detection were reported having the probability of finding hepatocellular carcinoma (HCC) at its early stage, but it is time-consuming and not cost-effective.
  • To improve the effectiveness and cost-effective of HCC surveillance program, close monitoring has been focused on patients with liver cirrhosis who have particularly high risk of HCC development.
  • METHODS: Total RNA was extracted from fresh specimens of HCC and liver cirrhosis.
  • Survivin mRNA amplification was performed by reverse transcription polymerase chain reaction (RT-PCR).
  • RESULTS: RT-PCR was performed in 17 HCC and 10 liver cirrhosis specimens, 11 HCC specimens showed 344bps molecular survivin DNA band in 1% agarose electrophoresis, but none of liver cirrhosis specimens showed positive band.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990202.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Hepatocellular carcinoma / Liver cirrhosis / Proliferation / Proliferation cell nuclear antigen / Survivin gene
  •  go-up   go-down


2. Stravitz RT: Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist. Gastroenterol Hepatol (N Y); 2006 May;2(5):346-354

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The referral of a patient with cirrhosis to a liver transplant center for evaluation is usually made by a local gastroenterologist.
  • The local gastroenterologist must also fully appreciate what constitutes a timely referral of a patient to a liver transplant center and the consequences of late referral.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2003 Aug;39(2):208-14 [12873817.001]
  • [Cites] Lancet. 2003 Nov 29;362(9398):1819-27 [14654322.001]
  • [Cites] J Hepatol. 2003 Jan;38(1):51-8 [12480560.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):937-40 [12949737.001]
  • [Cites] Gastroenterology. 1987 Aug;93(2):234-41 [3297907.001]
  • [Cites] Hepatology. 1990 Aug;12(2):273-80 [2391068.001]
  • [Cites] Semin Liver Dis. 2005;25(2):181-200 [15918147.001]
  • [Cites] Hepatology. 1992 Jul;16(1):132-7 [1352268.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):435-9 [11866284.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):1172-81 [9261620.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1171-4 [7557868.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):734-44 [11922571.001]
  • [Cites] Scand J Gastroenterol. 1987 Jan;22(1):117-23 [3563404.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):266-72 [12586291.001]
  • [Cites] Liver Transpl. 2005 Mar;11(3):249-60 [15719412.001]
  • [Cites] Semin Liver Dis. 2005;25(2):201-11 [15918148.001]
  • [Cites] Semin Liver Dis. 2005;25(2):143-54 [15918143.001]
  • [Cites] Hepatology. 2001 Feb;33(2):464-70 [11172350.001]
  • [Cites] Liver Transpl. 2005 Jun;11(6):679-83 [15915490.001]
  • [Cites] Gut. 1982 Jan;23(1):1-7 [7035298.001]
  • [Cites] Drugs. 1995 Mar;49(3):467-84 [7774516.001]
  • [Cites] Hepatology. 1995 Sep;22(3):753-8 [7657279.001]
  • [Cites] J Hepatol. 1986;3(1):75-82 [3745889.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1407-32 [15880505.001]
  • [Cites] J Hepatol. 2005;42 Suppl(1):S65-74 [15777574.001]
  • [Cites] Liver Transpl. 2005 Feb;11(2):124-33 [15666386.001]
  • [Cites] Hepatology. 2004 Mar;39(3):841-56 [14999706.001]
  • [Cites] Hepatology. 2002 Jan;35(1):105-9 [11786965.001]
  • [Cites] Clin Liver Dis. 2001 Aug;5(3):645-63 [11565135.001]
  • [Cites] Hepatology. 2001 Jul;34(1):28-31 [11431730.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):941-66 [12949738.001]
  • [Cites] N Engl J Med. 1988 Oct 13;319(15):983-9 [3262200.001]
  • [Cites] Am J Transplant. 2003 Dec;3(12):1481-7 [14629278.001]
  • [Cites] Hepatology. 1997 Jan;25(1):63-70 [8985266.001]
  • [Cites] Gut. 1979 Feb;20(2):133-6 [311747.001]
  • [Cites] Liver Transpl. 2002 Jul;8(7):582-7 [12089709.001]
  • [Cites] Liver. 1999 Jun;19(3):188-92 [10395037.001]
  • [Cites] Miner Electrolyte Metab. 1993;19(6):362-7 [8164617.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Mar;28(3):468-79 [15084905.001]
  • [Cites] Semin Liver Dis. 1999;19(4):439-55 [10643628.001]
  • [Cites] Hepatology. 1994 Jan;19(1):72-9 [8276370.001]
  • [Cites] Ann Intern Med. 1989 May 15;110(10):838-9 [2712463.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12 [15508073.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):286-90 [9445408.001]
  • [Cites] Am J Gastroenterol. 2003 Oct;98(10):2268-74 [14572578.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1372-80 [15521006.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):91-6 [12512033.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2193-7 [10445549.001]
  • [Cites] Ann Pharmacother. 2005 Jan;39(1):68-76 [15590870.001]
  • [Cites] Hepatology. 1990 Oct;12(4 Pt 1):716-24 [2210673.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):1968-76 [11467622.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Apr;17(4):462-6 [11982728.001]
  • [Cites] Clin Liver Dis. 2001 Aug;5(3):665-76 [11565136.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1680-5 [1568578.001]
  • [Cites] Hepatology. 1995 Aug;22(2):432-8 [7543434.001]
  • [Cites] Dig Dis Sci. 2001 Dec;46(12):2752-7 [11768269.001]
  • [Cites] Ann Intern Med. 1995 Apr 15;122(8):595-8 [7887554.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1005-14 [15057740.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):579-86 [9247479.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] Ann Intern Med. 1970 Sep;73(3):393-6 [5455989.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2343-51 [11007240.001]
  • [Cites] Hepatology. 2004 Jul;40(1):65-72 [15239087.001]
  • [Cites] N Engl J Med. 1999 Apr 1;340(13):988-93 [10099140.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):414-9 [10419924.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Nov;222(2):99-112 [10564534.001]
  • [Cites] Gastroenterology. 1981 Apr;80(4):800-9 [6970703.001]
  • [Cites] Hepatology. 2004 Mar;39(3):739-45 [14999692.001]
  • [Cites] Gastroenterology. 1980 Mar;78(3):512-7 [7351289.001]
  • [Cites] Liver Transpl. 2000 Jul;6(4):440-2 [10915165.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):503-8 [10685758.001]
  • [Cites] Transplantation. 2001 Aug 27;72(4):666-70 [11544428.001]
  • [Cites] Hepatology. 1988 Jul-Aug;8(4):966-8 [3391524.001]
  • (PMID = 28289338.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cirrhosis / liver failure / liver transplantation / portal hypertension
  •  go-up   go-down


3. Potter T, Tavernier R, Devos D, Beeumen KV, Duytschaever M: Predictors of Success After a First Circumferential Pulmonary Vein Isolation For Atrial Fibrillation. J Atr Fibrillation; 2009 Apr-May;1(6):161
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <b>Conclusions:</b> (1) Using the "circumferential pulmonary vein isolation" approach, the first catheter ablation leads to resolution of arrhythmia in ≈ 70% of symptomatic AF patients. (2) Independent predictors for freedom of AF after initial CPVI are duration of AF history and 3D LA volume. (3) Due to considerable overlap between failures and successes, these parameters can not be used to identify patients who should not undergo CPVI or in whom an additional ablation beyond CPVI is required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Heart Rhythm. 2005 Jan;2(1):42-8 [15851264.001]
  • [Cites] Circulation. 2002 Mar 5;105(9):1077-81 [11877358.001]
  • [Cites] Circulation. 2000 Nov 14;102(20):2463-5 [11076817.001]
  • [Cites] Circulation. 2003 Nov 11;108(19):2355-60 [14557355.001]
  • [Cites] JAMA. 2005 Jun 1;293(21):2634-40 [15928285.001]
  • [Cites] J Am Coll Cardiol. 2005 Jan 18;45(2):285-92 [15653029.001]
  • [Cites] Circulation. 2001 Nov 20;104(21):2539-44 [11714647.001]
  • [Cites] Circulation. 2004 Oct 12;110(15):2090-6 [15466640.001]
  • [Cites] Circulation. 2004 Jan 27;109(3):327-34 [14707026.001]
  • [Cites] Circulation. 1999 Sep 14;100(11):1203-8 [10484541.001]
  • [Cites] J Heart Valve Dis. 2007 Jan;16(1):76-83 [17315386.001]
  • [Cites] Europace. 2006 Sep;8(9):651-745 [16987906.001]
  • [Cites] J Cardiovasc Electrophysiol. 2006 Mar;17(3):251-5 [16643395.001]
  • [Cites] J Interv Card Electrophysiol. 2006 Apr;15(3):157-63 [16955362.001]
  • [Cites] J Cardiovasc Electrophysiol. 2004 Jun;15(6):692-7 [15175066.001]
  • [Cites] J Am Soc Echocardiogr. 2008 Jun;21(6):697-702 [18187293.001]
  • [Cites] J Cardiovasc Electrophysiol. 2008 Aug;19(8):807-11 [18363688.001]
  • [Cites] N Engl J Med. 1998 Sep 3;339(10):659-66 [9725923.001]
  • [Cites] J Am Coll Cardiol. 2004 Mar 17;43(6):1004-9 [15028358.001]
  • [Cites] Eur Heart J. 2005 Dec;26(23):2550-5 [16183686.001]
  • [Cites] Cardiovasc Res. 2002 May;54(2):230-46 [12062329.001]
  • [Cites] Arq Bras Cardiol. 2007 Feb;88(2):134-43 [17384829.001]
  • [Cites] J Interv Card Electrophysiol. 2006 Apr;15(3):145-55 [17019636.001]
  • [Cites] Europace. 2007 Dec;9(12):1129-33 [17923474.001]
  • [Cites] Heart Rhythm. 2006 Sep;3(9):1024-8 [16945795.001]
  • [Cites] J Am Coll Cardiol. 2002 Jul 3;40(1):100-4 [12103262.001]
  • [Cites] J Cardiovasc Electrophysiol. 2002 Feb;13(2):118-23 [11900284.001]
  • [Cites] J Cardiovasc Electrophysiol. 2006 Sep;17 (9):965-72 [16948740.001]
  • [Cites] Europace. 2005 Mar;7(2):95-103 [15763523.001]
  • [Cites] Europace. 2007 Jun;9(6):335-79 [17599941.001]
  • [Cites] Circulation. 2005 Aug 9;112(6):789-97 [16061740.001]
  • [Cites] Eur Heart J. 2007 Apr;28(7):836-41 [17395676.001]
  • [Cites] J Cardiovasc Electrophysiol. 2006 Oct;17(10):1080-5 [16989649.001]
  • (PMID = 28496618.001).
  • [Journal-full-title] Journal of atrial fibrillation
  • [ISO-abbreviation] J Atr Fibrillation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Ammerlaan AC, Houben MP, Tijssen CC, Wesseling P, Hulsebos TJ: Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation. Childs Nerv Syst; 2008 Jul;24(7):855-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation.
  • OBJECTIVE: We report on a patient who developed a meningioma more than two decades after removal at a young age of an atypical teratoid/rhabdoid tumour (AT/RT), which was due to a germline INI1 mutation, and radio- and chemotherapy.
  • MATERIALS AND METHODS: We present genetic evidence that the meningioma is not a recurrence or metastasis of the AT/RT and not due to the INI1 mutation, but is a radiation-induced tumour.
  • CONCLUSION: This is the first case illustrating that improved survival of young patients with an AT/RT after aggressive treatment may be gained at the cost of an increased risk for the development of radiation-induced, non-INI1-related tumours.
  • [MeSH-major] Chromosomal Proteins, Non-Histone / genetics. DNA-Binding Proteins / genetics. Meningioma / secondary. Mutation / genetics. Rhabdoid Tumor / genetics. Transcription Factors / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Apr;66(4):1403-6 [10739763.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):614-20 [10901233.001]
  • [Cites] Br J Cancer. 2001 Jan;84(2):199-201 [11161377.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1002-13 [15200115.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):474-9 [18087273.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1491-9 [15735125.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E9 [16398473.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):279-84 [16261613.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):97-111 [16855864.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Aug;13(4):272-7 [7547635.001]
  • (PMID = 18236049.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2413122
  •  go-up   go-down


5. Yang R, Tan X, Thomas AM, Shen J, Qureshi N, Morrison DC, Van Way CW 3rd: Crocetin Inhibits mRNA Expression for Tumor Necrosis Factor-α, Interleukin-1β, and Inducible Nitric Oxide Synthase in Hemorrhagic Shock. JPEN J Parenter Enteral Nutr; 2006;30(4):297-301

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crocetin Inhibits mRNA Expression for Tumor Necrosis Factor-α, Interleukin-1β, and Inducible Nitric Oxide Synthase in Hemorrhagic Shock.
  • The hypothesis of the present study is that treatment with crocetin at the beginning of resuscitation suppresses subsequent expression of messenger ribonucleic acid (mRNA) for tumor necrosis factor (TNF-α), interleukin-1 (IL-1β) and inducible nitric oxide synthase (iNOS).
  • Liver samples were collected for reverse transcription-polymerase chain reaction (RT-PCR) analysis of mRNA (TNF-α, IL-1β, iNOS, and β-actin).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28059007.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Tez S, Köktener A, Güler G, Ozişik P: Atypical teratoid/rhabdoid tumors: imaging findings of two cases and review of the literature. Turk Neurosurg; 2008 Jan;18(1):30-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumors: imaging findings of two cases and review of the literature.
  • Atypical teratoid/rhabdoid tumor (AT/RT) is a malignant embryonal central nervous system (CNS) tumor, manifesting in children, and composed of rhabdoid cells, with or without fields resembling a classical primitive neuroectodermal tumor (PNET), epithelial tissue and neoplastic mesenchyme.
  • Around 200 cases of CNS AT/RT have been documented in the literature.
  • Although the clinical and pathological findings have been defined in large series previously, and AT/RT has become increasingly recognized, awareness of typical AT/RT is important in making the correct diagnosis of this uncommon but probably underdiagnosed entity.
  • Neuroradiologists rarely mention AT/RT in their differential diagnosis and this paper presents two additional cases in which clinical and pathological findings are combined with neuroradiological presentation.
  • [MeSH-major] Brain Neoplasms / pathology. Magnetic Resonance Imaging. Rhabdoid Tumor / pathology. Teratoma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382974.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 18
  •  go-up   go-down


7. Casagrande R, Georgetti SR, Verri WA, Jabor JR, Santos AC, Fonseca MJ: Evaluation of functional stability of quercetin as a raw material and in different topical formulations by its antilipoperoxidative activity. AAPS PharmSciTech; 2006 Mar;7(1):E64-E71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no detectable loss of activity during 182 days (6 months) of storage at all tested temperatures (4°C, room temperature [RT], 37°C, and 45°C) for the raw material.
  • In conclusion, the results suggest that the activity of quercetin depends on iron chelation, and its posible usefulness as a topical antioxidant to prevent oxidative stress-induced skin damage depends on maintaining its antilipoperoxidative activity stored at RT, which avoids special storage conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1994 May;102(5):671-5 [8176246.001]
  • [Cites] Int J Cosmet Sci. 1995 Jun;17(3):91-103 [19245494.001]
  • [Cites] Free Radic Biol Med. 1999 Dec;27(11-12):1313-23 [10641726.001]
  • [Cites] Biochem Pharmacol. 1998 Oct 15;56(8):935-43 [9776303.001]
  • [Cites] Methods Cell Biol. 1978;20:411-81 [151184.001]
  • [Cites] Asia Pac J Clin Nutr. 1999 Mar;8(1):53-63 [24393737.001]
  • [Cites] Methods Enzymol. 1990;186:343-55 [2172711.001]
  • [Cites] Free Radic Biol Med. 1998 Jun;24(9):1355-63 [9641252.001]
  • [Cites] Chem Biol Interact. 1989;71(1):1-19 [2550151.001]
  • [Cites] Free Radic Biol Med. 2000 Aug;29(3-4):375-83 [11035267.001]
  • [Cites] J Biol Chem. 1949 Feb;177(2):751-66 [18110453.001]
  • [Cites] Toxicology. 2000 Nov 23;154(1-3):21-9 [11118667.001]
  • [Cites] Biochem Pharmacol. 1989 Sep 1;38(17):2859-65 [2476132.001]
  • [Cites] J Biol Chem. 1996 Feb 9;271(6):2929-34 [8621682.001]
  • [Cites] Methods Enzymol. 1978;52:302-10 [672633.001]
  • [Cites] Biochem Pharmacol. 1993 Jan 7;45(1):13-9 [8424806.001]
  • [Cites] Br J Pharmacol. 2002 May;136(1):136-42 [11976278.001]
  • [Cites] Biochem J. 1987 Apr 1;243(1):55-9 [3038086.001]
  • [Cites] Free Radic Biol Med. 1995 Oct;19(4):481-6 [7590397.001]
  • [Cites] Free Radic Biol Med. 2001 Oct 1;31(7):869-81 [11585705.001]
  • [Cites] Free Radic Biol Med. 1998 Jun;24(9):1455-61 [9641263.001]
  • (PMID = 28290025.001).
  • [ISSN] 1530-9932
  • [Journal-full-title] AAPS PharmSciTech
  • [ISO-abbreviation] AAPS PharmSciTech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; antioxidant / flavonoids / lipid peroxidation / quercetin / stability
  •  go-up   go-down


8. Moeller KK, Coventry S, Jernigan S, Moriarty TM: Atypical teratoid/rhabdoid tumor of the spine. AJNR Am J Neuroradiol; 2007 Mar;28(3):593-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor of the spine.
  • SUMMARY: Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant central nervous system neoplasm usually seen in young children and infants.
  • Prognosis for AT/RT is poor, with most patients dying within 1 year of presentation.
  • AT/RT most commonly occurs intracranially.
  • We present a case of AT/RT occurring in the thoracolumbar spine of a child and review available clinical and imaging findings in previously reported cases of spinal AT/RT.
  • [MeSH-major] Magnetic Resonance Imaging. Rhabdoid Tumor / pathology. Spinal Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353344.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Makuria AT, Rushing EJ, McGrail KM, Hartmann DP, Azumi N, Ozdemirli M: Atypical teratoid rhabdoid tumor (AT/RT) in adults: review of four cases. J Neurooncol; 2008 Jul;88(3):321-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid rhabdoid tumor (AT/RT) in adults: review of four cases.
  • Atypical teratoid/rhabdoid (AT/RT) tumor is a rare, highly malignant tumor of the central nervous system (CNS) most commonly found in children less than 5 years of age.
  • Since its histological appearance can be confused with other tumors, especially in adults, separating AT/RT from other neoplasms may be difficult.
  • Radiographically, two tumors were localized in the right fronto-parietal region, one was frontal and the other was found in the left temporal lobe.
  • Immunohistochemical staining showed that the tumor cells were positive for vimentin and reacted variably for keratin, epithelial membrane antigen (EMA), synaptophysin, neurofilament protein, CD34, and smooth muscle actin (SMA).
  • In adult examples of AT/RT, the diagnosis requires a high index of suspicion, with early tissue diagnosis and a low threshold for investigation with INI1 immunohistochemistry to differentiate this entity from other morphologically similar tumors.
  • Although the prognosis is dismal in pediatric population, long term survival is possible in adult AT/RT cases after surgery and adjuvant radiotherapy and chemotherapy.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Rhabdoid Tumor / metabolism. Rhabdoid Tumor / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1981 Jul;12(7):646-57 [7275104.001]
  • [Cites] Semin Cell Dev Biol. 1999 Apr;10 (2):189-95 [10441072.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):49-56 [11451202.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):121-6 [12622450.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2278-92 [9694794.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):729-37 [8391222.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):79-82 [16443951.001]
  • [Cites] Can J Neurol Sci. 1996 Nov;23(4):257-63 [8951203.001]
  • [Cites] Neuroradiology. 2000 May;42(5):363-7 [10872158.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1114-8 [10632935.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3461-7 [12429635.001]
  • [Cites] Acta Neuropathol. 1992;83(4):445-8 [1575023.001]
  • [Cites] J Neurooncol. 2005 Sep;74(3):311-9 [16132523.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jun-Jul;24(5):337-42 [12142780.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):1010-29 [8092393.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12311-5 [10535918.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6171-7 [11085541.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):223-7 [9024522.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):23-8 [15779233.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1033-8; discussion 1038 [15340816.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):247 [10477033.001]
  • [Cites] Neuropathology. 2002 Dec;22(4):252-60 [12564764.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):644-50 [15105654.001]
  • [Cites] Pediatr Radiol. 2006 Feb;36(2):126-32 [16341528.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):323-8 [11782395.001]
  • [Cites] Cancer. 1978 May;41(5):1937-48 [206343.001]
  • [Cites] Hum Pathol. 2001 Feb;32(2):156-62 [11230702.001]
  • [Cites] Cancer Res. 2004 May 15;64(10 ):3406-13 [15150092.001]
  • [Cites] Neuropathology. 2006 Feb;26(1):57-61 [16521480.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):49-55 [17377740.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):74-9 [9892189.001]
  • [Cites] Neurol India. 2003 Jun;51(2):273-4 [14571026.001]
  • [Cites] Ultrastruct Pathol. 1997 Jul-Aug;21(4):361-8 [9206001.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2002-6 [7801128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7748-53 [10884406.001]
  • [Cites] Mol Cell. 1999 Feb;3(2):247-53 [10078207.001]
  • (PMID = 18369529.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 Protein; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


10. Yu CP, Cheung JY, Chan JF, Leung SC, Ho RT: Prolonged survival in a subgroup of patients with brain metastases treated by gamma knife surgery. J Neurosurg; 2005 Jan;102(s_supplement):262-265

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival in a subgroup of patients with brain metastases treated by gamma knife surgery.
  • OBJECT: The authors analyzed the factors involved in determining prolonged survival (≥ 24 months) in patients with brain metastases treated by gamma knife surgery (GKS).
  • METHODS: Between 1995 and 2003, a total of 116 patients underwent 167 GKS procedures for brain metastases.
  • <sup>3</sup> The mean follow-up time was 9.2 months.
  • Certain factors were associated with increased survival time.
  • These were stable primary disease (21 of 23 patients), a long latency between diagnosis of the primary tumor and the occurrence of brain metastases (mean 28.4 months, median 16 months), absence of third-organ involvement, and repeated local procedures.
  • CONCLUSIONS: Aggressive local therapy with GKS, repeated GKS, and GKS plus surgery can achieve increased survival in a subgroup of patients with stable primary disease, no third-organ involvement, and long primary-brain secondary intervals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28306476.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; brain metastasis / gamma knife surgery / radiosurgery / survival
  •  go-up   go-down


11. Cave MC, Hurt RT, Frazier TH, Matheson PJ, Garrison RN, McClain CJ, McClave SA: Obesity, Inflammation, and the Potential Application of Pharmaconutrition. Nutr Clin Pract; 2008 Feb;23(1):16-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Obesity creates a low-grade systemic inflammatory response syndrome (SIRS) that is similar (but on a much smaller scale) to gram-negative sepsis.
  • This process involves up-regulation of systemic immunity, is characterized clinically by insulin resistance and the metabolic syndrome, and puts the patient at increased risk for organ failure, infectious morbidity, and mortality.
  • Through lipotoxicity and cytokine dysregulation, obesity may act to prime the immune system, predisposing to an exaggerated subsequent immune response when a second clinical insult occurs (such as trauma, burns, or myocardial infarction).
  • Specialized nutrition therapy for such patients currently consists of a hypocaloric, high-protein diet.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28056680.001).
  • [ISSN] 1941-2452
  • [Journal-full-title] Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  • [ISO-abbreviation] Nutr Clin Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Stadler P, Peters O: The importance of radiotherapy in AT/RT patients less than 3 years of age: in regards to Chen et al. (Int J Radiat Oncol Biol Phys 2006;64:1038-1043). Int J Radiat Oncol Biol Phys; 2006 Jul 15;65(4):1273; author reply 1273-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The importance of radiotherapy in AT/RT patients less than 3 years of age: in regards to Chen et al. (Int J Radiat Oncol Biol Phys 2006;64:1038-1043).
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Brain Neoplasms. Rhabdoid Tumor. Teratoma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1038-43 [16406394.001]
  • (PMID = 16798419.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic
  •  go-up   go-down


13. Ou D, Wang X, Metzger DL, Ao Z, Pozzilli P, James RFL, Chen L, Warnock GL: Suppression of Human T-Cell Responses to β-Cells by Activation of B7-H4 Pathway. Cell Transplant; 2006 May;15(5):399-410

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human islet cells express positive B7-H4 mRNA in RT-PCR assays, but not B7-H4 protein on cell surface in flow cytometric analyses.
  • To investigate the regulatory effects of activation of the B7-H4 pathway on the function of activated T cells of patients with type 1 diabetes (T1D), we have used our in vitro human experimental system, including human β-cell antigen-specific T-cell clones and human β-cell lines CM and HP62, as well as primary islet cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28871868.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; B7-H4 / Costimulatory molecules / Islet cell transplantation / Suppression of T-cell responses / Type 1 diabetes / β-Cell destruction
  •  go-up   go-down


14. Soufla G, Baritaki S, Sifakis S, Zafiropulos A, Spandidos DA: Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix. Int J Biol Markers; 2005 Jan - Mar;20(1):18-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.
  • Transcript levels of the above genes were assessed by RT-PCR analysis in a total of 44 cervical specimens. p53, Bcl-2, Bax and Mdm2 transcript levels were significantly different in the normal, CIN and cancer specimen groups (p=0.003, p=0.009, p=0.040 and p=0.001, respectively).
  • High-grade squamous intraepithelial lesions exhibited lower p53 and Bcl-2 mRNA levels than controls (p=0.002, p=0.016).
  • Our findings show that p53, Bax, Bcl-2 and Mdm2 mRNA expression levels correlate with the malignant transformation of the uterine cervix. mRNA coexpression patterns of the members of the pro- and anti-apoptotic family examined in cervical carcinogenesis were found to be disrupted in CIN and cancer, as already demonstrated at the protein level. (Int J Biol Markers 2005; 20: 18-27).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207100.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Popovic M, Ostapiak O, Chow T: Poster - Thurs Eve-34: Extended CT-range in RT planning of pelvic cancer treatment in presence of hip replacements. Med Phys; 2008 Jul;35(7Part2):3407

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poster - Thurs Eve-34: Extended CT-range in RT planning of pelvic cancer treatment in presence of hip replacements.
  • Our results indicate that data with extended CT range result in a better agreement between measured and calculated dose at the central position of the body phantom, as should be expected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512835.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computed tomography / Ionization chambers / Medical imaging / Therapeutics
  •  go-up   go-down


16. Mühlisch J, Schwering A, Grotzer M, Vince GH, Roggendorf W, Hagemann C, Sörensen N, Rickert CH, Osada N, Jürgens H, Frühwald MC: Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene; 2006 Feb 16;25(7):1111-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood.
  • Supratentorial primitive neuroectodermal tumors (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of the CNS represent a biological and clinical enigma, despite advances in both molecular techniques and clinical management for these two rare embryonal brain tumors of childhood.
  • We thus studied aberrant methylation of the genes RASSF1A and CASP8 and its consequence on expression in cell lines and primary tumors using a combination of semiquantitative methylation specific PCR (MSP), bisulfite sequencing and RT-PCR.
  • In all, 17 samples of autopsy-derived normal appearing brain served as controls.
  • Opposed to control tissues 19/24 sPNET and 4/6 AT/RT demonstrated aberrant methylation for the RASSF1A promoter region.
  • Treatment of cell lines using 5-Aza-2'-deoxycytidine (5AZA) alone or in combination with trichostatin A (TSA) succeeded in re-establishing expression of RASSF1A in cell lines derived from a renal rhabdoid, an AT/RT and a medulloblastoma.
  • A 5' CpG-rich region of CASP8 was methylated in normal tissues and in tumors.
  • However, CASP8 showed inconsistent expression patterns in normal and tumor tissues.
  • Our results indicate that aberrant methylation of the RASSF1A promoter region may be of importance in the origin and progression of sPNET and AT/RT while the analysed 5'-CpG rich region of the CASP8 gene does not seem to play an important role in these tumors.
  • Further studies of epigenetic changes in these rare tumors are warranted as their biology remains obscure and treatment efforts have been rather unsuccessfull.
  • [MeSH-major] Brain Neoplasms / genetics. DNA Methylation. Gene Silencing. Neuroectodermal Tumors, Primitive / genetics. Rhabdoid Tumor / genetics. Teratoma / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186793.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; M801H13NRU / Azacitidine
  •  go-up   go-down


17. Yoon HH, Powell M, Murphy K, Montgomery EA, Hafez MJ, Liu G, Forastiere AA, Benson AB, Kleinberg LR, Gibson MK, ECOG E1201-T1 Study Group: Outcome prediction based on single nucleotide polymorphisms (SNPs) in DNA repair paths in patients (pts) with esophageal adenocarcinoma (EAC) treated with preoperative (preop) cisplatin (C)-based chemoradiation (CRT): Results from the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol; 2009 May 20;27(15_suppl):4530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed whether SNPs in DNA repair paths are associated with complete pathologic response (pCR) in EAC pts who received C-based CRT followed by surgery.
  • METHODS: Patients and specimens: Pretreatment biopsy or post-CRT resection samples were obtained from pts (EAC, stage II-IVa) treated on a randomized phase II trial, E1201 (n=86), of preop CRT (RT to 45 Gy).
  • Arm A: Preop C 30 mg/m<sup>2</sup> + irinotecan (I) 50 mg/m<sup>2</sup> days (d) 1, 8, 22, 29 with RT.
  • Arm B: Preop C 30 mg/m<sup>2</sup> + paclitaxel (P) 50 mg/m<sup>2</sup> d 1, 8, 15, 22, 29 with RT.
  • Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight (Sequenom) for all SNPs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962996.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Gerard J, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P, Vendrely V, Conroy T, Francois E, Montoto-Grillot C: Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2. J Clin Oncol; 2009 May 20;27(15_suppl):LBA4007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963298.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Billan S, Abdah-Bortnyak R, Mezid F, Bernstein Z, Gez E, Nasrallah H, Kuten A: Neoadjuvant docetaxel, cisplatin, and 5-fluorouracil before concurrent chemoradiotherapy or concurrent cetuximab-radiotherapy in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol; 2009 May 20;27(15_suppl):e17045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study assessed the feasibility of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by concurrent chemoradiotherapy (CHT-RT) or concurrent cetuximab-radiotherapy.
  • METHODS: Induction chemotherapy consisted of TPF (docetaxel 75 mg/m(2), cisplatin 75 mg/m(2), 5-fluorouracil 750 mg/m(2)/d continuous infusion for 96 h) every three weeks, followed by CHT-RT regimen (radiotherapy 70 Gy total dose fractionated at 2Gy per day, 5 days a week concurrently with weekly cisplatin 40 mg/m(2) or cetuximab with loading dose of 400 one week before starting radiotherapy and 250 weekly during the radiotherapy) 4-7 weeks later.
  • RESULTS: Between march 2007 and november 2008, 29 previously untreated patients (19 male and 4 female) with stage III-IV squamous cell carcinoma of the oral cavity, larynx, oropharynx, or hypopharynx were included to the study.
  • The stage distribution was as follows: stage II, 1 patient; stage III, 14 patients; and stage IV, 14 patients.
  • Toxicity from IC included neutropenia Gr III,IV 25%,neutropenic fever 9%, mucositis and diarrhrea Gr III, IV 22% .
  • The toxicity from the concurrent phase included mucositis Gr III-IV in 70% of patients,dermatitis Gr III-IV in 43% and no case of neutropenia Gr III-IV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961767.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Kaley TJ, Raizer JJ, Paleologos N, Kewalramani T, Grimm S, Louis DN, Cairncross JG, Abrey LE: Phase II trial of temozolomide (TMZ) followed by myeloablative chemotherapy with autologous peripheral blood progenitor cell rescue (APBPCR) for newly diagnosed anaplastic oligodendroglioma: An Oligodendroglioma Study Group trial. J Clin Oncol; 2009 May 20;27(15_suppl):2055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiotherapy (RT) remains the standard therapy, but not without toxicity.
  • Exploiting the chemosensitivity of these tumors using myeloablative chemotherapy with APBPCR is a potential strategy to defer RT.
  • Patients with surgical gross total resection who maintained response or patients who responded to temozolomide (CR or PR defined as >50% reduction in tumor) were eligible for myeloablative chemotherapy with thiotepa 250mg/m2/day for three days followed by busulfan 3.2mg/kg/day for three days, followed by APBPCR.
  • RESULTS: 19 patients (16 AO, 2 AOA, 1 low-grade oligodendroglioma with radiographic features suggestive of high-grade tumor) with a median age of 42 (28-56) and KPS of 90 (70-100) were enrolled.
  • 2 of the 10 patients who underwent APBPCR recurred, one at 16.1 and one at 34.2 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964668.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. de Vreeze RS, de Jong D, Nederlof PM, Ruijter HJ, Boerrigter L, Haas RL, van Coevorden F: Multifocal myxoid liposarcoma: Metastasis or second primary? A molecular biological analysis. J Clin Oncol; 2009 May 20;27(15_suppl):10576

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal myxoid liposarcoma: Metastasis or second primary? A molecular biological analysis.
  • : 10576 Background: The metastatic or second primary nature of multifocal myxoid/round cell liposarcoma (MRLS), defined as tumor presentation in at least two separate sites before manifestation in the lungs, is a matter of debate with essential clinical consequences.
  • Moreover, in solid tumors, analysis of loss of heterozygozity (LOH) has proven its value for clonality analysis.
  • Using RT-PCR, the detailed molecular characteristics of FUS-CHOP and EWS-CHOP breakpoints were determined.
  • RESULTS: In all patients, tumor sites showed identical FUS-CHOP exon fusion products.
  • In all other patients, LOH analysis was highly suggestive of clonal relation and no evidence for interpretation of a second primary tumor was found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963785.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Rampias T, Sasaki C, Psyrri A: Effect of human papillomavirus (HPV) 16 E6 and E7 gene silencing on epidermal growth factor receptor (EGFR) phosphorylation status in HPV16&lt;sup&gt;+&lt;/sup&gt;oropharyngeal cancer cell lines. J Clin Oncol; 2009 May 20;27(15_suppl):e17006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phospho-EGFR (Tyr<sup>1068</sup>), (Tyr<sup>845</sup>), (Tyr<sup>992</sup>), (Tyr<sup>1045</sup>) and total EGFR protein levels before and after silencing were then analyzed by western blotting in 147T and 090 oropharyngeal cancer cell lines.
  • RESULTS: Quantitative RT-PCR analysis showed reduction in E6/E7 mRNA levels up to 85% the level in uninfected or control shRNA infected cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Spensley S, Gilmore JA, Kenny J, Dunne M, Clayton-Lea A, Thirion PG: Functional outcome of malignant spinal cord compression treated with radiotherapy alone: A prospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional outcome of malignant spinal cord compression treated with radiotherapy alone: A prospective analysis.
  • : e20623 Background: Malignant spinal cord compression (MSCC) is a major oncological complication.
  • The management of Impending Malignant Spinal Cord Compression (IMSCC) remains unclear.
  • Radiotherapy (RT) is often the sole management of both entities.
  • METHODS: All pts with MSCC and IMSCC treated by RT in our institution were screened for 2 national trials (ICORG 05-03/07-11).
  • The primary tumours were haematological [13 pts], lung [10], prostate [8], renal cell [6] and breast [5].
  • 2D RT was used with varying radiation schedules: 20Gy/5fractions (f) [32 pts], 30Gy/10f [12] and other [10].
  • New sphincter dysfunction after RT was seen in 2 pts with IMSCC.
  • CONCLUSIONS: The functional outcome of MSCC treated by RT alone remains poor, with minimal mobility and sphincter improvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961600.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Huddart RA, James ND, Adab F, Syndikus I, Jenkins P, Rawlings C, Hendron C, Lewis R, Rogers S, Hall E, BC2001 Investigators: BC2001: A multicenter phase III randomized trial of standard versus reduced volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339). J Clin Oncol; 2009 May 20;27(15_suppl):5022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5022 Background: Radiotherapy (RT) is an alternative to radical cystectomy in the management of muscle invasive bladder cancer.
  • Limitations are probability of attaining and maintaining local tumour control and risk of late bladder toxicity.
  • BC2001 tests whether concomitant chemotherapy (CT) improves loco-regional control and whether RT volume modification reduces late toxicity without detriment to tumour control.
  • METHODS: Pts were randomized in a 2x2 factorial design to (i) RT vs RT + concomitant CT (5FU 500mg/m<sup>2</sup> d1-5 wks 1 & 4 + mitomycin C 12mg/m<sup>2</sup> d1) and/or (ii) standard RT to tumour and whole bladder with 1.5cm margin (sRT) vs reduced volume RT (rvRT) where tumour + 1.5cm margin was treated to 100(±5)% target dose and remaining bladder received 80% target dose.
  • RT dose was 55Gy/20F or 64Gy/32F according to local practice.
  • RT volume comparison results (primary endpoint RTOG toxicity at 1 yr) are reported.
  • Target sample size was 480 pts but the RT randomisation closed early due to slow recruitment.
  • There was no difference in loco-regional disease-free survival (LRDFS: HR = 1.06, 95% CI: 0.62-1.84) nor overall survival (HR = 0.99, (0.61 - 1.35)) between randomised RT groups.
  • 2yr LRDFS is 71% in both RT groups.
  • CONCLUSIONS: RT in the modern era can attain local control in most patients with T2-T3 bladder cancer.
  • Modifying standard RT volumes had minimal effect on local control and toxicity in this trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962919.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Palmer S, Wallace D, Bonner M, Raggl R, Chapieski L, Janzen L, Knight S, Boyle R, Armstrong C, Gajjar A: A longitudinal study of processing speed among children treated for medulloblastoma (MB), supratentorial primitive neuroectodermal tumor (SPNET), or atypical teratoid rhabdoid tumor (ATRT). J Clin Oncol; 2009 May 20;27(15_suppl):10028

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A longitudinal study of processing speed among children treated for medulloblastoma (MB), supratentorial primitive neuroectodermal tumor (SPNET), or atypical teratoid rhabdoid tumor (ATRT).
  • High risk (HR, n = 55) patients received 36 - 39.6 Gy CSI and 3D conformal boost to the primary site to 55.8 -59.4 Gy.
  • Average-risk (AR, n=119) patients received 23.4 Gy CSI, 3D conformal boost to the primary site to 55.8 Gy.
  • Those who had posterior fossa syndrome were excluded (n = 26) resulting in 148 patients who completed 459 neuropsychological evaluations using the Woodcock Johnson Tests of Cognitive Abilities-III over a period of 0.03 -4.94 years postdiagnosis.
  • RESULTS: Multivariate modeling revealed a statistically significant decline in processing speed for those < 7 years of age at time of diagnosis (-3.83 points per year, p = 0.003).
  • Those who were > 7 years at diagnosis did not experience a significant change (.86, NS).
  • HR patients experienced greater declines (-.82) than those who were AR (-0.29), but neither slope was statistically significant.
  • CONCLUSIONS: Young age at diagnosis is a prominent risk factor for processing speed impairment among survivors of pediatric embryonal tumors.
  • This study represents the largest comparison of processing speed ability among patients treated for pediatric embryonal tumors with conventional or reduced dose CSI and adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962588.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Lai A, Nghiemphu P, Green R, Spier L, Peak S, Phuphanich S, Fehrenbacher L, Kolevska T, Polikoff J, Cloughesy T: Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. J Clin Oncol; 2009 May 20;27(15_suppl):2000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2000 Background: Bevacizumab (BV) is a humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF).
  • In this trial, we evaluate the safety and efficacy of BV combined with standard of care radiation (RT) and temozolomide (TMZ) and radiation (RT) for newly-diagnosed GBM.
  • Primary outcome measure is overall survival; the secondary outcome measure is TTP and 12-month survival.
  • Therapy began between 3-5 weeks of surgery with BV (10 mg/kg every 2 weeks), TMZ (75 mg/m2 daily), and external beam RT (30 x 200 Gy) on the same day.
  • Preliminary TTP by Kaplan-Meier analysis is promising compared to that of a UCLA/KP control group of patients that received the conventional RT/TMZ regimen.
  • CONCLUSIONS: Addition of BV to the standard regimen of TMZ and RT for newly-diagnosed GBM is well-tolerated and shows promising efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964565.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Salazar LG, Slota M, Wallace D, Higgins D, Coveler AL, Dang Y, Childs J, Bates N, Waisman J, Disis ML: A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer.
  • : 3054 Background: HER2 is overexpressed in 25% of breast cancers and plays a role in the malignant transformation of cells.
  • DNA-based vaccines offer a strategy to immunize against multiple tumor antigens and are able to elicit both CTL and T helper immune responses.
  • A phase I study was conducted to evaluate the safety and immunogenicity of a DNA-based vaccine encoding the HER2 ICD.
  • METHODS: 44 subjects with stage III and IV HER2+ breast cancer in complete remission were enrolled sequentially into 2 vaccine arms (22 subjects/arm) and received 10μg pNGVL3-hICD (Arm 1) or 100μg pNGVL3-hICD (Arm 2).
  • All vaccines were admixed with 100μg GM-CSF and given i.d. monthly for a total of 3 vaccines.
  • Vaccine site biopsies were analyzed for plasmid persistence via RT-PCR, 1 and 6 months after vaccination.
  • Vaccine-related toxicity in both arms was primarily grade I/II; no cardiac or grade IV toxicity was observed.
  • ELISPOT and RT-PCR analysis for Arm 2 are on-going.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961998.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Jagsi R, Abrahamse P, Griggs JJ, Katz SJ: Adjuvant radiotherapy use in a population-based sample of breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):617

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 617 Background: Previous studies have suggested underutilization and socioeconomic disparities in use of adjuvant radiotherapy (RT) among patients with breast cancer.
  • Rates of RT receipt were based on patient report.
  • These were then stratified based on recurrence risk in the absence of RT (3 groups based on tumor size and grade for DCIS pts, 2 groups separating pts over 70 with Stage I, ER+ tumors from others undergoing BCS for invasive disease, and 3 groups based on tumor size and nodal status for those undergoing mastectomy for invasive disease).
  • RESULTS: Among 306 pts undergoing BCS for DCIS, 85.6% received RT (77.9% of pts at low recurrence risk, 84.8% at intermediate risk, and 95.8% at high risk).
  • Among 1018 pts undergoing BCS for invasive disease, 93.6% received RT (83.6% of low-risk patients and 94.9% of others).
  • Among 661 pts undergoing mastectomy for invasive disease, 39.3% received RT (81.5% of pts at high-risk, 44.5% at intermediate-risk, and 12.1% at low risk).
  • In separate multivariate logistic regression models including risk grouping and sociodemographic variables for each population, there were no significant associations between RT receipt and race, education, or income.
  • Among pts receiving RT, delay was reported by 15.9% of the DCIS group, 19.5% of those treated for invasive disease after BCS, and 27.4% of those treated for invasive disease after mastectomy.
  • CONCLUSIONS: RT use is high after BCS with little evidence of socioeconomic disparities.
  • Less RT use in patients with lower expected benefit suggests that legitimate clinical uncertainty influences decision-making.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961489.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Koutcher L, Fury M, Wolden S, Zhang Z, Mo Q, Zelefsky M, Kraus D, Sherman E, Pfister D, Lee N: Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis. J Clin Oncol; 2009 May 20;27(15_suppl):6042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis.
  • : 6042 Background: Both concurrent CDDP/RT and C/RT have been shown in randomized trials to yield superior disease control compared to RT alone in LAHNC, but no randomized trial has compared them.
  • METHODS: From 3/1/06 - 4/1/08, 175 patients were retrospectively identified who received definitive treatment for LAHNC with CDDP (planned total dose 100 mg/m<sup>2</sup> Q3 weeks X 3) and RT (n = 125) or C (400 mg/m<sup>2</sup> load; 250 mg/m<sup>2</sup> weekly) and RT (n = 50).
  • Patients who received prior RT, additional systemic therapy, and/or surgery to the primary site were excluded.
  • Additional CDDP and C features: male sex, 86 v 78%; stage IV, 70 v 68%; and oropharynx, 78 v 70%.
  • Median RT dose (70 Gy), RT length (46 days), and Karnofsky performance status (KPS) (90%) were the same; alcohol/tobacco use was similar.
  • For OS analysis, the concordance probability estimates were .67 for using drug choice alone and .80 for using drug choice, T stage, RT dose, and KPS.
  • CONCLUSIONS: CDDP/RT and C/RT were used to treat somewhat different populations with LAHNC.
  • The observed superiority of CDDP/RT compared to C/RT in LF, DFS, and OS may reflect patient selection issues.
  • However, preliminary multivariate modeling suggests that CDDP/RT remains the preferred option for fit patients pending further analyses and prospective studies comparing these regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Nguyen PL, Chen MH, Beard CJ, Loffredo M, Renshaw AA, Suh WW, Kantoff PW, D'Amico AV: Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol; 2009 May 20;27(15_suppl):5129

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa).
  • : 5129 Background: 6 months of AST+RT was shown to improve survival vs. RT alone in men with unfavorable-risk localized PCa, but it is unknown if this benefit applied to all risk subgroups.
  • METHODS: Among 206 men with clinical T1b-T2b PCa and at least 1 unfavorable feature (PSA>10 or Gleason >=7 or MRI evidence of T3 disease) randomized to 70Gy of RT with or without 6 months of AST, we performed post-randomization subgroup analyses within four subgroups defined by both risk group (high risk [Gleason 8-10 or PSA >20] or intermediate risk [all others]), and by ACE-27 comorbidity level (no/limited comorbidity or moderate/severe comorbidity).
  • Within the 4 subgroups a log-rank test was used to compare Kaplan Meier estimates of survival (requiring p < 0.05/4 or p < 0.0125 to adjust for multiple comparisons) and within the 2 risk groups we used Cox multivariable analysis (MVA) to assess the association of treatment with the risk of death after adjusting for known prognostic factors.
  • In men with no or minimal comorbidity, estimates of survival were significantly higher among those who received AST+RT vs. RT alone, regardless of whether they had intermediate risk disease (90.9 vs. 85.8% at 7yrs, p = 0.009) or high-risk disease (88.9% vs. 51.2% at 7yrs, p = 0.007).
  • In men with moderate or severe comorbidity, no difference in survival was observed after AST+RT vs. RT in intermediate risk (p = 0.2) or high risk (p = 0.5).
  • After adjusting for known prognostic factors, treatment with RT as compared to AST+RT was associated with an increased risk of death in men with intermediate (AHR: 3.0 [95% CI: 1.3 to 7.2]; p = 0.01) and high risk disease (AHR: 3.3 [95% CI: 0.94 to 11.3]; p = 0.06) in a model that adjusted for the interaction between treatment and comorbidity.
  • CONCLUSIONS: Among men with T1b-T2b prostate cancer who have no or minimal comorbidity, the addition of 6 months of AST to RT was associated with improved survival in men with both intermediate risk and high-risk disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964400.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Tosoni A, Franceschi E, Ermani M, Bacci A, Volpin L, Lombardo L, Ravenna G, Pinna G, Poggi R, Brandes AA: MGMT methylation status as a prognostic factor in anaplastic astrocytomas. J Clin Oncol; 2009 May 20;27(15_suppl):2052

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated only pts who met the following inclusion criteria: age >18 years; PS 0-2; histological diagnosis of AA; postoperative radiotherapy (RT) and chemotherapy (CT).
  • The log-rank test was employed to evaluate the significance of the prognostic variables.
  • This datum should provide the background to improve the therapeutic index with temozolomide concurrent with and adjuvant to RT in AA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964674.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Greven K: Can serial PET/CT imaging during and after chemoradiation treatment assist in individualizing therapy for patients with squamous cell cancer of the head and neck? J Clin Oncol; 2009 May 20;27(15_suppl):e17022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17022 Background: PET/CT imaging with FDG has the potential advantage over conventional imaging of demonstrating metabolic changes in tumors early in the course of chemoradiation which may aid in individualization of therapy for patients.
  • METHODS: Sixteen patients with stage III/IV head and neck cancer were prospectively entered on a study to evaluate the role of PET/CT between March 2006 and July 2007.
  • The max standard uptake values (SUV) were recorded in the primary tumors.
  • In addition CT imaging was examined and the maximum dimensions of the primary tumor were recorded.
  • RESULTS: Three patients have recurred at the primary site and follow-up ranges from 15-30 months.
  • The change in SUV at 2 weeks, 4 weeks, post RT 6 weeks and 3 months compared to baseline for the 3 patients with local recurrence and the 13 patients who remain disease free were -7%, -62%, -50%, and -16% compared to -34%, -62%, -77%, and -81%, respectively.
  • In contrast CT imaging demonstrated that tumor measurements at 2 weeks, 4 weeks, post RT 6 weeks, and 3 months steadily decreased in both groups with mean changes in the recurrence group and in the locally controlled group of -11%, -46%, -77%, and -100% and -47%, -57%, -73%, and -99%, respectively.
  • CONCLUSIONS: Changes in SUV from PET/CT were significantly predictive of tumor recurrence compared to CT imaging alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961700.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Mazloom A, Zangeneh AH, Teh BS, Paulino AC: Extraneural metastasis of medulloblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2065 Background: Medulloblastoma is the most common childhood intracranial tumor to spread extraneurally.
  • Factors analyzed included age, time interval to ENM, CNS involvement at the time of ENM, location of ENM, treatment, and outcome.
  • Of patients with available data regarding location of RT after ENM, 87% of patients received this treatment to the site of ENM.
  • The 1-year OS for patients with and without radiotherapy (RT) after ENM was 58% and 35%, respectively (p = 0.019).
  • For patients without CNS involvement at the time of ENM the 1-year OS for those treated with and without RT was 82% and 51%, respectively (p = 0.030), however RT did not significantly improve OS for those with CNS involvement.
  • 1-year OS of patients with time interval to ENM of <18 months was 25% while those with time interval greater than or equal to 18 months it was 61% (p = 0.001).
  • CONCLUSIONS: Negative prognostic factors for patients with ENM include CNS involvement at the time of ENM, lung or liver involvement, and duration to ENM <18 months.
  • Patients without CNS involvement who received RT after ENM had an OS and DFS benefit compared to those not receiving RT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964691.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Lordick F, Meyer Zum Büschenfelde C, Thuss-Patience P, Röthling N, Geinitz H, Budach V, Schumacher G, Friess H, Siewert JR, Peschel C: Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol; 2009 May 20;27(15_suppl):e15507

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  • Pts received weekly CET 250mg/m2 plus RT 25 x 1.8 Gy (cumulative dose 45 Gy) d1-33.
  • Surgery was scheduled 4-6 weeks after RT.
  • Of 6 pts treated in cohort 3, 1 pt developed grade 3 diarrhea and mucositis.
  • CONCLUSIONS: 2 weeks of CET (400mg/m<sup>2</sup> and 250mg/m<sup>2</sup>) followed by weekly CET (250mg/m<sup>2</sup>) plus OX 50mg/m<sup>2</sup> d1,8,22,29, 5-FU 225 mg/m<sup>2</sup>/d d1-5,8-12,15-19,22-26,29-33 and RT 45 Gy (1.8Gy/f) was shown to be safe as neoadjuvant treatment for locally advanced ESCC.
  • The anti-tumor activity of this regimen is promising and is being further investigated in an ongoing phase II study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962237.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Drappatz J, Norden AD, Wong ET, Lassman AB, Doherty L, LaFrankie D, Gerard M, Phan P, Schiff D, Wen PY: Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 2031 Background: There is increasing evidence that angiogenesis inhibition may potentiate the effects of radiation therapy (RT) and chemotherapy in patients with glioblastoma (GBM).
  • In addition, inhibition of the epidermal growth factor receptor (EGFR) may be of therapeutic benefit, as EGFR is often upregulated in GBM and contributes to radiation resistance.
  • We conducted a phase I study of vandetanib, an inhibitor of VEGFR2 and EGFR, in patients with newly-diagnosed GBM in combination with RT and temozolomide (TMZ).
  • METHODS: Using a standard 3 + 3 dose escalation design, 13 newly-diagnosed GBM patients received vandetanib with RT (60 Gy) and concurrent TMZ 75 mg/m<sup>2</sup> daily, followed by adjuvant TMZ for up to 12 cycles (150-200 mg/m<sup>2</sup> on days 1-5 of each 28 day cycle).
  • 2/6 patients developed DLTs (grade 5 gastrointestinal hemorrhage and grade 3 thrombocytopenia in one patient and grade 4 neutropenia in one patient).
  • CONCLUSIONS: These data suggest that vandetanib may be combined with RT and TMZ in GBM patients.
  • A randomized phase II study in which patients receive RT and TMZ with or without vandetanib 100 mg daily is underway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964631.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Ahunbay EE, Peng C, Chen GP, Narayanan S, Yu C, Lawton C, Li XA: An on-line replanning scheme for interfractional variationsa). Med Phys; 2008 Aug;35(8):3607-3615

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel online replanning strategy to correct for interfraction anatomic changes in real time is presented.
  • The proposed SAM-SWO scheme is practically comparable to full-scope reoptimization, but is fast enough to be implemented for on-line adaptive replanning, enabling dose-guided RT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28525032.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Cone beam computed tomography / Dose-volume analysis / Dosimetry / IGRT / Intensity modulated radiation therapy / Medical image segmentation / Medical imaging / Multileaf collimators / Optimization / Self assembly / adaptive radiotherapy / image segmentation / interfractional variations / planning / radiation therapy / replanning
  •  go-up   go-down


37. Speranza L, De Lutiis MA, Shaik YB, Felaco M, Patruno A, Tete' A, Mastrangelo F, Madhappan B, Castellani ML, Conti F, Vecchiet J, Theoharides TC, Conti P, Grilli A: Localization and activity of iNOS in normal human lung tissue and lung cancer tissue. Int J Biol Markers; 2007 Jul - Sep;22(3):226-231

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent investigations of NO expression in tumor tissue indicated that, at least for certain tumors, NO may mediate one or more roles during the growth of human cancer.
  • We localized iNOS in these tissues by immunohistochemistry and tested the mRNA expression by RT-PCR, the protein level by Western blot, and the protein activity by radiometric analysis.
  • The results demonstrate different expression, localization and activity of iNOS in normal versus tumor tissue.
  • This is suggestive of a role for NO production from iNOS in human lung cancer because high concentrations of this short molecule may transform to highly reactive compounds such as peroxynitrite (ONOO-); moreover, through the upregulator NF-kB, they can induce a chronic inflammatory state representing an elevated risk for cell transformation to cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207135.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


38. Avallone A, Delrio P, Di Gennaro E, Pecori B, Aloi L, Tatangelo F, Petrillo A, Budillon A, Caracò C, Sandomenico C, Comella P: Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts). J Clin Oncol; 2009 May 20;27(15_suppl):e14546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of two different schedules of bevacizumab (BEV) with oxaliplatin (OXA), raltitrexed (TOM), levo-folinic acid (LFA), and 5-fluorouracil (5-FU) during preoperative (preop) pelvic RT in high-risk locally advanced rectal cancer (HR-LARC) patients (pts).
  • : e14546 Background: OXA, RTX, 5FU, and LFA during preop pelvic RT produced a high rate of complete (TRG1) or subtotal (TRG2) tumor regression in HR-LARC.
  • BEV might enhance response to chemoradiotherapy (CH-RT), but scheduling of BEV could be critical.
  • Therefore, we added BEV to CH-RT in two different schedules to evaluate their feasibility and activity.
  • According to the Simon's two-stage design, assuming a hypothesis of a 50% TRG1 (α=0.05, β=0.20), at least 6/16 TRG1 should be obtained to continue pts accrual in every schedule.
  • Pts received 3 biweekly courses(c) of OXA (100 mg/m2)/TOM (2.5 mg/m2) on day 1, and 5FU (800 mg/m2)/LFA(250 mg/m2) on day 2 during pelvic RT (45 Gy).
  • Changes of circulating endothelial cells (CECs)assessed by flow cytometry in 17 (7 A; 10 B) pts, and glucose metabolism evaluated by FDG-PET in 27 (15 A; 12 B) pts after 1st c of CT were used as surrogate markers of tumor response.
  • The Mann-Whitney test assessed the differences in CECs and FDG-PET related to schedules.
  • TME was planned 8 wks after CH- RT.
  • All but one pt (A) completed the planned CH-RT.
  • Grade 3/4 neutropenia was the most common toxicity with schedule A (7 pts, 44%), while it never occurred with schedule B.
  • CONCLUSIONS: These data suggest the relevance of BEV scheduling during preop CT-RT to optimize safety and efficacy of the combination treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Simonelli M, Banna G, Navarria P, Di Ieva A, Zucali P, De Vincenzo F, Gaetani P, Condorelli R, Rodriguez Y Baena R, Scorsetti M, Santoro A: Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):e13037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13037 Background: Anaplastic astrocytoma (AA), oligodendroglioma (AOD), and oligoastrocytoma (AOA) are rare tumors showing variable outcome due to their histological heterogeneity and different chemo- and radio-sensitivity.
  • Currently, the addition of chemotherapy to radiotherapy (RT) for newly diagnosed anaplastic gliomas is not sustained by available data.
  • METHODS: Since September 2004, following initial surgery, patients (pts) with histologically confirmed anaplastic glioma, Karnofsky Performance Status (KPS) ≥40, adequate organ function, no prior chemotherapy, were treated with RT to limited fields once daily at 2 Gy per fraction, 5 days a week, for a total of 60 Gy with concomitant TMZ (75 mg/m<sup>2</sup> for 7 days a week) followed by 6 cycles of maintenance TMZ at 200 mg/m<sup>2</sup> on days 1-5 every 28 days.
  • Nine pts (32%) underwent tumor complete resection, 10 partial resection (36%), and 9 (32%) tumor biopsy.
  • In 1 patient with AOD RT and concomitant TMZ were interrupted at 44 Gy because of cerebral oedema, while in 1 patient with AA maintenance TMZ was suspended due to cumulative myelosuppression.
  • Frequent mild toxicities were grade 1-2 nausea/vomiting (17 pts-63%), and grade 1-2 asthenia (8 pts-30%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Perez SA, Bisias S, Kallinteris NL, Ardavanis A, Georgakopoulou KG, Apostolikas N, Thanos A, Papamichail M, von Hofe E, Baxevanis CN: Results from the first phase I clinical study of the novel Ii-Key/HER2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All pts had standard treatment prior to vaccinations, including surgery (S) (n=9); hormonal treatment (HT) (n=4); S+HT (n=6); S+HT+radiotherapy (RT); (n=2); S+chemotherapy (CH) (n=2); HT+RT (n=2); CH (n=3) and S+HT+CH (n=2).
  • During vaccinations, 11 pts were free of any treatment, while 5 pts who had progressive disease received additional chemotherapy; the remainder received HT alone or combined with RT.
  • Toxicity and side effects beyond grade-2 were not observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Dandona MA, Morgensztern D, Auethavekiat V, Adkins D, Thorstad W, Nussenbaum B, Zhang Q, Kuperman DI: Survival for nasopharyngeal cancer with distant metastatic disease at presentation. J Clin Oncol; 2009 May 20;27(15_suppl):e17004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e17004 Background: Nasopharyngeal carcinoma (NPC) is a unique form of head and neck cancer, with distinct epidemiology and sensitivity to chemotherapy (CT) and radiation (RT).
  • METHODS: The SEER database was searched for patients with NPC who have distant metastatic disease at presentation, defined as extent of disease (EOD10) code 85, aged 20 or older, diagnosed between 1988 and 2003.
  • Survival probability was estimated by Kaplan-Meier method and covariate effects were examined using log-rank tests.
  • Parameters evaluated include age, gender, race, tumor grade, and use of RT.
  • Five patients were excluded from subsequent analysis because RT data was not available.
  • RT was administered to 114 patients (66.3%).
  • Outcomes were significantly improved for patients treated with RT compared to those not receiving it, with the 5-year OS rates of 28% versus 3% (p < 0.0001) respectively.
  • CONCLUSIONS: Although SEER lacks information on performance status, site of metastases, and CT use, our data shows that selected patients with metastatic NPC may achieve prolonged survival, particularly if RT is used.
  • It is unclear whether RT is a determinant of better OS or an epiphenomenon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961652.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Nicholas MK, Lucas RV, Arzbaecher J, Paleologos N, Krouwer H, Malkin M, Omar A, Vick NA: Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):2016

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II study.
  • : 2016 Background: Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor.
  • Current standard treatment consists of fractionated radiotherapy (RT) with daily oral temozolomide (TMZ) chemotherapy followed by 6 months of adjuvant TMZ chemotherapy.
  • Because GBM is characterized by vascular proliferation and produces high levels of vascular endothelial growth factor (VEGF), attempts to better control the disease with targeted anti-angiogenesis therapies are underway.
  • METHODS: Subjects received standard regional RT to a dose of 60 Gy in 30 fractions with dailyconcurrent TMZ (75 mg/m2) within 3-5 weeks of diagnosis.
  • Four weeks after RT/TMZ, subjects received 5 consecutive daily TMZ doses (150-200 mg/m2) administered every 28 days.
  • Of these, 4 were receiving RT/TMZ, 18 were receiving TMZ/BV and 1 was delayed post-RT/TMZ due to local wound infection.
  • Eleven of those off-study never received BV due to: study withdrawal (n = 2), toxicity during RT/TMZ (n = 3) and post-RT/TMZ progression (n = 6).
  • Duration of treatment, inclusive of RT/TMZ, ranged from 27 to 523 days.
  • CONCLUSIONS: The co-administration of TMZ/BV following RT/TMZ for newly diagnosed GBM is safe and well-tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964582.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Pasini F Sr, de Manzoni G, Stievano L, Grandinetti A, Maluta S, Capirci C, Durante E, Bonetti A, Zanoni A, Cordiano C: Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): A phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of neoadjuvant combined modality therapy with weekly docetaxel (D) and cisplatin (P), 5-fluorouracil (5-FU) continuous infusion (c.i.), and concurrent radiotherapy (RT) on pathological response rate in esophageal cancers (EC): A phase II study.
  • In a phase I study (Pasini et al, Ann Oncol 2005) we demonstrated the feasibility of a novel protocol of neoadjuvant chemoradiation.
  • The primary end point was the pathological response rate, the secondary end points were survival and toxicity.
  • Treatment consisted of D 35 mg/m2 and P 25 mg/m2 d 1,8,15,29,36,43,50,57 plus 5-FU 180 mg/m2 c.i. d 1-21 and 150 mg/m2 c.i. d 29-64; concurrent RT (50 Gy) started on d 29.
  • Surgery was performed 6 to 8 weeks after completion of RT.
  • The overall median survival was 50 mo; median survival times of Others, pTrm, and pCR subsets were 17, 42 months and not reached, respectively (p<0.001).
  • During chemoradiation, grade 3-4 hematological toxicity occurred in 10 pts (13.5%); grade 3-4 non-hematological toxicities occurred in 22 pts (30%), mostly in the last 2 weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963008.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Rudin CM, Senzer N, Stephenson J, Loesch D, Burroughs K, Police SR, Hallenbeck P: Phase I study of intravenous Seneca Valley virus (NTX-010), a replication competent oncolytic virus, in patients with neuroendocrine (NE) cancers. J Clin Oncol; 2009 May 20;27(15_suppl):4629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4629 Background: NTX-010 is a naturally occurring replication competent picornavirus with potent and selective tropism for human NE tumors, including small cell cancers and carcinoid.
  • NTX-010 elicts rapid cytolysis in vitro and durable responses following IV dosing in multiple xenograft models.
  • METHODS: A first-in-human phase I study of IV NTX-010 was conducted across 5 log-increment dose cohorts from 10<sup>7</sup> vp/kg to 10<sup>11</sup> vp/kg, in patients with NE cancers.
  • Evidence of intratumoral viral replication includes delayed kinetics in serum viral titer, post-infusion serum titers greater then the dose administered and positive immunohistochemistry and/or RT-PCR signal for viral antigens in tumor mass despite Ab production.
  • A single IV dose of 10<sup>11</sup> vp/kg of NTX-010 is safe, has predictable viral kinetics, and shows promising activity against NE tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N: GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). J Clin Oncol; 2009 May 20;27(15_suppl):4616

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary outcome is feasibility using proportion of patients (pts) receiving > 80% planned dose for each component.
  • METHODS: Pts with previously untreated inoperable LAPC, M0, measurable disease, ECOG 0-2 were given Gem (1000mg/m<sup>2</sup> d1 + d15 q28), Ox (100mg/m<sup>2</sup> d2 + d16 q28) in both ind (1 cycle) & con (3 cycles), & 5FU 200mg/m<sup>2</sup>/d over 6 weeks during RT of 54Gy in 30 fractions of 1.8Gy.
  • Worst grade (G) for anaemia (10%); fatigue, nausea (8%); diarrhoea, vomiting, neutropenia, infection (4%); stomatitis, anorexia (2%) was G3.
  • The extended duration of LC and a subset who had a very prolonged benefit may be due to patient selection but equally may suggest an incremental benefit from more intensive systemic therapy requiring further study in controlled trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964183.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Bhattacharyya S, Raina V, Shukla NK, Shukla S, Kumar R, Hedau S, Kumar G, Bharti AC, Rath GK, Das BC: Circulating tumor DNA in plasma of breast cancer patients from India. J Clin Oncol; 2009 May 20;27(15_suppl):e22213

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating tumor DNA in plasma of breast cancer patients from India.
  • Recently, the level of cell free circulating tumor DNA in blood plasma or serum of patients with variety of tumors are being considered as reliable non-invasive diagnostic tool but no study has been done in India.
  • Concentration of cell free plasma DNA was analyzed by 3 methods viz. nanodrop spectro-photometry, integrated density value (IDV) of PCR products of Exon 7 of p53 gene and quantitative real time PCR (cycles threshold converted to genome equivalent).
  • RESULTS: Mean free plasma DNA concentration as determined by both Q-RT PCR and IDV in cancer patients was found to be significantly higher in advanced stage breast cancer patients than in controls (genome equivalent 18850 vs 431; IDV 17912 vs 4197; p=0.001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964168.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Selvaggi G, Righi L, Ceppi P, Bacillo E, Billè A, Pandiscia S, Ardissone F, Scagliotti GV, Papotti M: Relationship of thymidylate synthase levels to outcome of malignant pleural mesothelioma patients treated with pemetrexed-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):7508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of thymidylate synthase levels to outcome of malignant pleural mesothelioma patients treated with pemetrexed-based chemotherapy.
  • : 7508 Background: Pemetrexed has shown activity in malignant pleural mesothelioma (MPM) but scanty data are available on the expression of thymidylate synthase (TS), its most important molecular target.
  • In addition, mRNA extraction was performed in 23 micro-dissected tissues and TS relative levels quantified by RT-PCR.
  • Survival probability was assessed by Kaplan-Meier method and results compared by log-rank test.
  • RESULTS: Thirty-two patients had progressive disease and 24 had died at the time of the analysis.
  • Median time to progression (TTP) and median survival time (MST) were 11.6 and 20.9 months, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963478.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Comandone A, Boglione A, Pochettino P, Berno E, Inguì M, Papotti M, Borasio P, Maggi G, Brach Del Prever E, Gino G: Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas. J Clin Oncol; 2009 May 20;27(15_suppl):e21509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcomas of the lungs and mediastinum: Clinicopathological study and therapy results of Piedmontese Group for Sarcomas.
  • : e21509 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart).
  • RESULTS: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • CONCLUSIONS: Primary sarcomas of the lungs and mediastinum have a very severe prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Fusi A, Busse A, Ochsenreither S, Rietz A, Keilholz U: Expression of stem cell markers in circulating melanoma cells. J Clin Oncol; 2009 May 20;27(15_suppl):e22056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22056 Background: Within circulating tumor cells there may be a subset of cell with stem cell (tumor initiating) characteristics able to develop distant metastasis.
  • METHODS: Between 50 and 100 ml of peripheral blood were collected from 12 melanoma patients with various tumor burden as well as three healthy volunteers.
  • Blood samples were enriched for tumour cells by CD45 depletion of the leukocyte fraction using magnetic beads separation (EasySep, Stem Cell Technologies. Inc.).
  • The remaining material was stained with antibodies for the markers Melan-A/Mart-1 (Dako) and HMB45 (Dako), CD133 (Miltenyi Biotec) and nestin (R&D System) and analysed by flow cytometry (BD FACSCalibur).
  • Ten ml of blood were further processed and CD133, nestin, Melan-A/Mart-1 transcripts were quantified by Real Time RT-PCR (LightCycler, Roche Diagnostic).
  • The population of cells with lower expression of the melanoma markers showed at the same time higher expression of nestin and CD133 (5.9% vs. 1.3% and 10.2% vs. 6.7% respectively).
  • Nestin results were in good accordance to the FACS data (nestin: r=0.55; CD133: r=0.23; Pearson test).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963238.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. El-Khoueiry AB, Pohl A, Danenberg K, Cooc J, Zhang W, Yang D, Singh H, Shriki J, Iqbal S, Lenz HJ: Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV). J Clin Oncol; 2009 May 20;27(15_suppl):4056

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue samples from 68 patients with mCRC were analyzed. mRNA was extracted from laser-capture-microdissected tumor tissue. cDNA was prepared by reverse transcription and quantitation of the candidate genes was performed using a fluorescence- based real-time detection method (TaqMan).
  • Allele specific RT-PCR was performed to determine Kras mutation status in codons 12 and 13.
  • CONCLUSIONS: To our knowledge, this is the first report of a potential association between Kras status as well as gene expression levels of VEGFR2, ERCC-1 and EGFR and clinical outcome to FOLFOX/BV therapy in pts with mCRC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Mitsiades N, Schultz N, Taylor BS, Hieronymus H, Satagopan J, Scardino PT, Reuter VE, Sander C, Sawyers C, Scher HI, Prostate Cancer Genome Project Group: Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies. J Clin Oncol; 2009 May 20;27(15_suppl):5002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Gene expression profiles of 30 normal prostate tissue samples, 131 primary prostate carcinomas (PCas) and 16 metastatic PCas, generated using Affymetrix Exon arrays, were interrogated for levels of 40 mRNAs encoding AR, SHBG, 28 enzymes involved in androgen synthesis and 10 enzymes involved in androgen inactivation.
  • For individual tumors, a transcript was considered to be overexpressed or underexpressed when its levels were >2 SDs higher or lower, respectively, than its average levels in normal tissue.
  • RESULTS: Metastatic PCas expressed higher average transcript levels for AR and several steroidogenic enzymes, including SRD5A1 and SRD5A3, than primary PCas and normal prostate tissue.
  • Expression of SRD5A2, CYP3A4, CYP3A5, and CYP3A7 mRNAs was decreased both in primary and metastatic tumors compared to normal prostate tissue.
  • In analysis involving AR and 28 steroidogenic transcripts in individual tumors, all (16/16) metastatic PCas overexpressed at least one transcript (range: 2-14, median: 5 transcripts) compared to normal tissue, while 100/131 (76%) primary PCas overexpressed at least one transcript (range: 2-16, median: 2).
  • Overexpression of AR or steroidogenic enzymes may serve as a biomarker (e.g. by detection via RT-PCR in circulating tumor cells) to predict for sensitivity to these agents and guide patient selection for participation in clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Schuetze S, Rutkowski P, Van Glabbeke MM, Rankin C, Rubin BP, Lazar A, Debiec-Rychter M, Gelderblom H, Hohenberger P, van Oosterom AT: Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). J Clin Oncol; 2009 May 20;27(15_suppl):10520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10520 Background: DFSP is an infiltrative, low-grade, dermal tumor with propensity to recur locally and occasionally metastasize.
  • Two distinct phase II trials of imatinib in patients (pts) with locally advanced or metastatic DFSP were conducted, 1 in North America (SWOG) with confirmed objective response rate and 1 in Europe (EORTC) with 14 week progression-free rate as primary end-points.
  • In the SWOG trial confirmation of t(17;22) by RT-PCR was performed after enrollment, imatinib was started at 400mg daily and response was assessed every 8 weeks.
  • One patient did not have DFSP on central review, lacked t(17;22) and thus was ineligible.
  • Median time to progression was 1.7 yrs.
  • Response rates and time to progression did not appear to differ between pts taking 400 mg daily versus 400 mg bid.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Lassman AB, Oligodendroglioma Study Group: Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of outcomes among more than 1,000 patients with newly diagnosed anaplastic oligodendroglial tumors.
  • : 2014 Background: Treatment of anaplastic oligodendroglial tumors is controversial.
  • Early results of randomized trials suggest chemotherapy (CT) with procarbazine-lomustine-vincristine (PCV) before or after radiotherapy (RT) improves progression-free but not overall survival (OS) versus RT alone.
  • It is unknown if CT alone affects outcome versus CT&RT, or if temozolomide (TMZ) compares favorably with PCV.
  • Treatment was: observation (82, 8%), RT alone (n = 210, 20%), RT then chemotherapy (283, 27%), RT + CT concurrently (118, 11%), CT alone (205, 19%), CT then RT (137, 13%), or other (19, 2%).
  • Median time to progression (TTP) and OS were 2.8 and 6.5 years, respectively, with median follow up of 4.1 years (0.03-20.8) on surviving patients (n = 560, 53%).
  • 1p19q co-deletion was observed in 292 (48%) and no deletion in 232 (38%) of 606 tested tumors.
  • Median TTP was longer following CT&RT (sequential or concurrent) than CT alone (3.7 vs. 2.6 years, p = 0.0007), but median OS did not differ (6.6 vs. 7.1 years, p = 0.8); co-deletion was more common with CT alone than CT&RT (p < 0.0001, χ<sup><sup>2</sup></sup>), although restricting analysis of CT&RT versus CT to the co-deletion cohort yielded analogous results (median TTP 7.2 vs. 3.8 years, p = 0.011; OS 7.9 vs. 10.4 years, p = 0.26).
  • CT alone did not appear to shorten OS versus CT&RT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Yap JC, Yang GY, Fakih M, Mashtare T, Bullard Dunn K, Kuvshinoff BW, Smith J, Khushalani NI, Gibbs JF: Primary adenocarcinoma of the anus: a 22-year SEER population database analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e15072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the anus: a 22-year SEER population database analysis.
  • A search of the SEER database (1973 to 2005) was carried out to evaluate the pattern of radiation (RT) and surgical treatment.
  • METHODS: The search of the SEER database revealed 1,008 pts who had pathologically confirmed anal cancers with either SCCA or AdenoCa.
  • Within the SCCA group, 14 (1.5%) had abdominoperineal resection (APR) in combination with external beam RT, and 795 (83.3%) had RT only with non-APR local surgical treatment inclusive of excision.
  • Remaining 145 SCCA pts (15.2%) had non-APR local surgical treatment only without RT or had no treatment.
  • Within the AdenoCa group, 10 (18.5%) had APR in combination with external beam RT, and 21 (38.9%) had RT only with non-APR local surgical treatment inclusive of excision.
  • Remaining 23 AdenoCa pts (42.6%) had non-APR local surgical treatment only without RT.
  • Among the SCCA subset, there was no signficant difference in the 10-yr OS between the APR versus the RT pts (71% vs. 65%, p=0.78).
  • On the other hand, among the AdenoCa subset, pts who had APR had better 10-yr OS than RT pts (53.8% vs. 0%, p=0.03) Conclusions: For localized anal SCCA, RT yielded equivalent overall survival as compared to APR.
  • RT only without APR might not be sufficient treatment in these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964572.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Mir AR Jr, Sazawal Sazawal S, Saxena A, Saxena R: High-sensitivity detection of M351T, F317L, and F311C BCR-ABL kinase domain mutation in chronic myeloid leukemia patients treated with novel tyrosine kinase inhibitors (TKIs) imatinib and dasatinib. J Clin Oncol; 2009 May 20;27(15_suppl):7061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred CML patients were treated with imatinib at 400 mg/day from 2 to 4 years .They were diagnosed by RT-PCR for BCR-ABL transcripts.
  • After 11 months of dose escalation, 15/20 lost M351T mutation but remaining five who resist M351T mutation, developed a more fatal mutation called gate keeper mutation T315I.
  • CONCLUSIONS: ASO-PCR proved to be a very economical, sensitive, and rapid technique for detection of KD mutations M351T, F317L, and F311C ABL mutation and is more sensitive than mutation detection by sequencing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Diaz JJ Sr, Thomas MB, Hernandez E: Outcome analysis of stage II and III cervical carcinoma: Importance of optimal radiation therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nonsurgical therapy consisting of radiation (RT) with or without chemotherapy (CT) was offered to all patients.
  • Optimal dose of RT was defined as a minimal cervical dose exceeding 7000 cGy, point A dose of 8000-9000 cGy and treatment duration not exceeding 56 days.
  • Only 21 (44%) patients received optimal RT.
  • Only 2 patients treated with carboplatin had grade 3 or 4 toxicity.
  • There were only 4 PF (19%) and 4 DF (19%) in the 21 patients who received optimal RT.
  • The estimate of probability of 5-year pelvic failure rate in patients who received optimal therapy and patients who received suboptimal therapy was 23% vs. 48% (p = 0.2) .
  • On subset analysis patients who received optimal RT had a better 5-year OS (72% versus 45%, p = 0.09).
  • CONCLUSIONS: Optimal RT is crucial for successful treatment of advanced CC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961530.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Sarkaria JN, Galanis E, Wu W, Giannini C, Jaeckle KA, Doyle L, Uhm J, Brown P, Dietz AB, Buckner J: NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients. J Clin Oncol; 2009 May 20;27(15_suppl):2019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients.
  • We previously demonstrated significant synergy of the mTOR inhibitor sirolimus with RT in glioma xenografts.
  • METHODS: The standard cohorts of 3 design was applied with dose escalation of weekly IV CCI-779 in combination with standard TMZ/RT.
  • CCI-779 was given during both RT (60 Gy)/TMZ (75 mg/m2 daily) and adjuvant TMZ (200 mg/m2 daily x 5 every 28 days).
  • RESULTS: A total of 17 patients were enrolled.
  • CCI-779 therapy during RT/TMZ was well tolerated at dose level 0 (25 mg CCI-779, n = 3) and dose level 1 (50 mg CCI-779, n = 6) with 1 of 9 patients experiencing a DLT (Gr 3 fatigue).
  • Despite reasonable tolerance during RT/TMZ, the overall regimen was associated with a high rate of infection associated with lymphopenia.
  • In contrast to our 18% grade 5 infection rate, only 4% grade 3 (no grade 4/5) infections were observed in 26 other CTEP-sponsored clinical trials involving 1,006 patients treated with CCI-779.
  • Further infections were avoided on this trial after CCI-779 therapy was limited to RT/TMZ.
  • CONCLUSIONS: Although CCI-779 in combination with RT/TMZ was well-tolerated, adjuvant therapy with TMZ/CCI-779 was associated with an increased risk of opportunistic infections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Cabrera A, Jantus Lewintre E, Sirera R, Honguero A, Gil M, Blasco A, Sanmartin E, Arnau A, Guijarro R, Camps C: Expression of angiogenic genes in resectable non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e22207

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is known that angiogenesis is an essential event for solid tumour growth.
  • Vascular endothelial growth factor (VEGF) family of ligand and receptors (VEGFR) are described as powerful angiogenic factors.
  • METHODS: We performed real-time quantitative polymerase chain reaction (RT-qPCR) to assess the expression of VEGF, PlGF, VEGFR1 and VEGFR2 in frozen lung cancer specimens from untreated NSCLC patients who had undergone surgical resection (n=21).
  • RESULTS: Our results show that tumor samples have higher expression of PlGF than normal tissue.
  • We found a significant correlation between the levels of expression of PlGF and the tumor size (p= 0.023, Spearman's test), whereas no relation was found between the expression of the genes and the histology or stage of disease.
  • CONCLUSIONS: Our results reveal that, in NSCLC, PlGF mRNA is higher in tumor than in normal tissue and is positively correlated with the tumor size and with the expression of angiogenic receptors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964135.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Indelicato DJ, Keole SR, Shahlaee AH, Morris CG, Gibbs CP, Scarborough MT, Islam S, Marcus RB: Ewing tumors of the chest wall: Local control and long-term outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):e21501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing tumors of the chest wall: Local control and long-term outcomes.
  • : e21501 Background: Primary sarcomas of the lungs and mediastinum are rare and few data are reported on treatment and results of therapy.
  • 5 mediastinal tumours were located as follows: 2 in anterior part, 1 in posterior and 2 in the middle (sarcomas of the heart).
  • RESULTS: In 20/31 cases the tumour was immediately resected (3 mediastinal masses and 17 lung sarcomas).
  • The histology were: peripheral nerve tumour 7, leiomyosarcoma 4, MFH 2, fibrosarcoma 2, liposarcoma 1, angiosarcoma 2, undifferentiated sarcoma 1, solitary fibrous tumour 2, rhabdomyosarcoma 2, synovialsarcoma 2, pulmonary artery sarcoma 1, pleuropolmonary blastoma 1, malignant hemangiopericytoma 1, mixoid chondrosarcoma 1, ectopic osteosarcoma 1, aggressive fibromatosis 1.
  • Only 4 pts received neoadjuvant chemotherapy, 11 adjuvant CT, 5 exclusive CT + RT for inoperable disease.
  • CONCLUSIONS: Primary sarcomas of the lungs and mediastinum have a very severe prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963390.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Yamada Y, Yamamoto S, Ohtsu A, Suzuki Y, Nasu J, Yamaguchi K, Denda T, Tsuji A, Hara Y, Boku N, Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group: Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. J Clin Oncol; 2009 May 20;27(15_suppl):4535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Blocks from endoscopic biopsy specimens of primary lesions before chemotherapy were available from 365 of 704 pts in JCOG9912.
  • Using laser-captured microdissection and real-time RT-PCR, we analyzed mRNA expression of ERCC1, TS, DPD in paraffin-embedded specimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962991.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Chilukuri S, Surana S, Mohanty PP, Kuppuswamy R: Impact of interobserver variability in delineating clinical target volumes (CTV) for head and neck intensity modulated radiation therapy (IMRT): Potential for a geographical miss. J Clin Oncol; 2009 May 20;27(15_suppl):e17013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: This study documents that the volumes of uncertainty surrounding the PTV, which could contain subclinical disease, in fact receive a significant amount of RT dose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961730.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Seitz S, Schally AV, Gluck S, Rick F, Szalontay L, Hohla F, Papadia A, Köster F, Ortmann O, Buchholz S: Effective treatment of triple-negative breast cancer with targeted cytotoxic somatostatin analogue AN-162 (AEZS-124). J Clin Oncol; 2009 May 20;27(15_suppl):619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of SSTR in HCC 1806 human TNBC cell line was detected by RT-PCR.
  • In vivo, AN-162 significantly (p<0.05) inhibited tumor growth of HCC 1806 xenografts compared to Control, DOX and the unconjugated mixture of DOX+RC-160 from day 14 and the inhibition remained significant until the end of the study on day 35.
  • CONCLUSIONS: Our results indicate that treatment with targeted cytotoxic somatostatin analogue AN-162 produces a greater inhibition of tumor growth than DOX alone in somatostatin receptor positive TNBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961493.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Kronenwett R, Stropp U, Briasoulis E, Gehrmann M, Razis E, Hennig G, Bafaloukos D, Wirtz RM, Economopoulos T, Fountzilas G: Utility of a multigene prognostic algorithm in combination with TP53 expression for prediction of benefit from adjuvant taxane-containing chemotherapy in node-positive breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):593

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of a multigene prognostic algorithm in combination with TP53 expression for prediction of benefit from adjuvant taxane-containing chemotherapy in node-positive breast cancer patients.
  • METHODS: The 211 N+ patients included in this study were treated in the context of a randomized two-arm phase III study (E-T-CMF vs. E-CMF) investigating adjuvant dose-dense sequential chemotherapy with epirubicin (E) followed by CMF with or without paclitaxel (T).
  • RNA was isolated from formalin-fixed, paraffin-embedded tissue samples, using a Siemens proprietary method, followed by kinetic one-step RT-PCR for assessment of mRNA expression of the nine SPS genes, TP53 and two normalization genes.
  • Optimal cutoff for low or high TP53 expression was defined on the basis of a ROC curve in SPS high-risk patients.
  • Distant metastasis-free survival (MFS) and overall survival (OS) were estimated by the Kaplan-Meier method and compared using the log-rank test.
  • CONCLUSIONS: Our prognostic algorithm combined with TP53 mRNA expression predicts the benefit from the addition of paclitaxel to E-CMF and might be used for identification of patients who should be considered for adjuvant taxane therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960707.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Tanja FN, Hoffmann O, Aktas B, Solomayer E, Wallwiener D, Becker S, Kimmig R, Kasimir-Baur S: Expression profile of CTC and corresponding tumors in primary breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of CTC and corresponding tumors in primary breast cancer patients.
  • However, treatment decisions are based on expression of predictive markers (ER; PR, HER-2) of the primary tumor.
  • Based on current studies, presence of MRD may be reflected by the detection of circulating tumor cells (CTC).
  • Therefore, the aim of the study was to characterize CTC by multiplex-PCR for the expression of HER-2, ER, and PR and compare the expression profiles of CTCs with those of the corresponding primary tumors.
  • METHODS: CTC from blood of 431 patients with primary breast cancer were analyzed for EpCAM, MUC1, and HER-2 transcripts with the AdnaTest BreastCancer (AdnaGen AG, Germany).
  • Expression of the ER and PR receptor was assessed in an additional RT-PCR.
  • The ER, PR and HER2 receptor status of the primary tumors was determined by immunohistochemistry.
  • ER positivity of the primary tumor was demonstrated in 45/58 (78%) of these patients, PR positivity in 41/58 (71%) patients and HER-2 in 9/58 (16%) patients, respectively.
  • The concordance rate between ER, PR, and HER-2 status of CTCs and the primary tumor was 29%, 25%, and 53%, respectively Interestingly, the spread of CTC was mostly found in triple negative tumors (p = 0.01) and CTC in general were mostly found to be triple-negative regardless of the ER, PR, and HER-2 status of the primary tumor.
  • CONCLUSIONS: Since the expression profile between CTC and the primary tumor differs, the consequence for the selection of adjuvant treatment targeting minimal residual disease has to be further evaluated in clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960691.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Plastaras JP, Haynes JC, Mick R, Hertan LM, Urdaneta AI, Metz JM: Effect of nutritional status and support on survival in esophageal cancer patients undergoing combined modality therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e20641

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A retrospective review was performed of 132 pts treated with curative intent using radiation (RT) between 1986 and 2007 at the Hospital of the University of Pennsylvania.
  • Esophagectomy was performed in 70%, with adjuvant RT in 60% and neoadjuvant RT in 40%.
  • During RT, oral or enteral nutritional supplements were provided to 77% of pts and intravenous fluids (IVF) were given to 38%.
  • Median absolute and percentage weight loss during RT were 6.2 lbs and 3.8%, respectively.
  • Univariable Cox regression analysis demonstrated a statistically significant association between weight loss of ≥5 lbs during RT and worse survival (HR 1.74, 95% CI 1.09 - 2.79, p=0.02).
  • Patients who received only nutritional supplements during RT survived significantly longer (p=0.03) than pts who received IVF regardless of nutritional supplementation (HR 2.12, 95% CI 1.12 - 4.01) or pts who received neither nutritional supplements nor IVF (HR 1.8, 95% CI 1.03 - 3.14).
  • CONCLUSIONS: Weight loss during RT predicted for worse survival.
  • Nutritional factors before and during RT may be important in outcomes in patients with esophageal cancer and may be modifiable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961661.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Mora J, Cruz O, Parareda A, Guillen A, Puy R, Massaguer S, de Torres C, Garcia G, Costa JM: Treatment of childhood glial tumors with cisplatin and irinotecan. J Clin Oncol; 2009 May 20;27(15_suppl):10062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood glial tumors with cisplatin and irinotecan.
  • : 10062 Background: Childhood glial tumors are heterogeneous neoplasias for which non-surgical management is controversial.
  • After a pilot study suggesting that irinotecan/cisplatin (I/C) may be effective in children (Mora et al, Neuro Oncol 2007), we initiated a phase II prospective trial with the aim of avoiding radiation therapy for low grade's (LG) and improve outcome for high grade's (HG).
  • Weekly Irinotecan (50 mg/m2 and 65 mg/m2 the last 2 cycles) and Cisplatin (30 mg/m2) for four consecutive weeks (1 cycle), and a total of 4 cycles was used.
  • Fourteen tumors were WHO grades I-II gliomas (LGG), 10 grade III (6 gliomas, 2 anaplastic ependymomas and 2 AT/RT), and 6 had no biopsy (3 brainstem (BST) and 3 optic-pathway tumors (OPT)).
  • Primary sites included: 4 supratentorial, 8 BST, 9 OPT, 2 cerebellar, and 7 spinal.
  • Prior to the I/C regimen, gross total resection was performed in 7 and biopsy in 14 tumors; 9 patients received chemotherapy and 5 radiotherapy.
  • All but 6 patients, 2 because of C allergy and 4 BST because of progression, completed the protocol, with no grade 3-4 side effects.
  • Twenty (90%) of 22 patients with evaluable clinical symptoms had a complete and rapid response, with objective functional recovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962497.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Hahn NM, Stadler WM, Zon RT, Waterhouse DM, Picus J, Nattam SR, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ: A multicenter phase II study of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC): Hoosier Oncology Group GU-0475. J Clin Oncol; 2009 May 20;27(15_suppl):5018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Metastatic or unresectable chemonaive UC patients (pts) with an ECOG performance status of 0-1 received C 70 mg/m<sup>2</sup> iv d1, G 1,000-1,250 mg/m<sup>2</sup> iv d1, 8, and B 15 mg/kg iv d1 on a q21d cycle for up to 8 cycles.
  • Gemcitabine was reduced to 1,000 mg/m<sup>2</sup> iv d1, 8 for all subsequent pts after 7 thromboembolic events were noted in the first 17 pts.
  • The primary endpoint was progression free survival (PFS).
  • 14 (33%) and 6 (14%) pts experienced grade 3 or 4 hematologic toxicity (4 pts - thrombocytopenia, 2 pts - neutropenic fever).
  • Grade 3 or 4 nonhematologic toxicity was observed in 24 (56%) and 9 (21%) pts (DVT/PE - 9 pts, CNS hemorrhage/proteinuria/hypertension - 1 pt each) Best RECIST response was: complete response 6 pts (17%, 95% CI 6-33%), partial response 18 pts (50%, 95% CI 33-67%); with overall response rate of 67% (95% CI 51-82%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962899.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Partap S, Murphy PA, Vogel H, Barnes PD, Edwards MS, Fisher PG: Efficacy and tolerability of intrathecal liposomal cytarabine for central nervous system embryonal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and tolerability of intrathecal liposomal cytarabine for central nervous system embryonal tumors.
  • METHODS: We reviewed all patients at our institution treated with liposomal cytarabine for primary central nervous system (CNS) embryonal tumors-MB, primitive neuroectodermal tumor (PNET), and atypical teratoid rhabdoid tumor (ATRT).
  • RESULTS: A cohort of 17 patients were treated with liposomal cytarabine at diagnosis of CNS embryonal tumor (2 PNET, 3 ATRT) or relapse (12 MB [7 average-risk, 5 high-risk]); nine had leptomeningeal metastases.
  • A total of 102 doses were administered (lumbar IT 76, Ommaya intraventricular 36) with a mean of six treatments (range 1-16).
  • All six evaluable patients with malignant cerebrospinal fluid (CSF) cytology and treated with at least two doses cleared their spinal fluid (mean 3 doses, range 1-5).
  • No patient developed malignant CSF cytology while receiving liposomal cytarabine.
  • All patients with neoplastic meningitis cleared malignant cells from their spinal fluid after treatment with IT liposomal cytarabine and systemic chemotherapy.
  • Our findings warrant a phase II trial of liposomal cytarabine in newly diagnosed or recurrent CNS embryonal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Bossi P, Parolini D, Bergamini C, Locati LD, Orlandi E, Franceschini M, Palazzi M, Olmi P, Potepan P, Licitra L: TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC). J Clin Oncol; 2009 May 20;27(15_suppl):6046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following CT, pts received full doses radiotherapy (RT) concurrent with cisplatin 100 mg/sm q 21 days.
  • Stage IV pts were 60%, stage III 34%, and 6% stage II.
  • RT dose ranged from 64 Gy to 70 Gy (median 70 Gy).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961922.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Castiglioni A, Bencardino K, Tamburini AM, Monno A, Albarello L, Staudacher C, Ronzoni M, Doglioni C, Rovere-Querini P, Manfredi A: Characterization of innate responses elicited by neoadjuvant radio-chemotherapy for rectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15044 Background: The neoadjuvant chemo-radiotherapy (CT-RT) has improved the treatment of locally advanced rectal cancer reducing the local recurrence.
  • In order to increase the rate of pathological complete remissions in our Institution we intensified both the CT schedule adding oxaliplatin to 5-FU and the RT program with tomotherapy.
  • The aim of this study was to verify: whether the pattern of innate response elicited by the neoadjuvant CT-RT is heterogeneous among pts and whether this information can be used to identify which pts will benefit from the treatment.
  • METHODS: We collected samples of T3N+M0 rectal cancer pts before, during and after neoadjuvant CT-RT (3 cycles of oxaliplatin + 5-FU; 45 Gy).
  • At each time point we characterized circulating monocytes by flow cytometry, infiltrating macrophages by immunoistochemistry (IHC) and selected inflammatatory molecules by ELISA.
  • This event was transient and apparently causally related to the treatment since it abated at the later time point.
  • Moreover, it correlated with sensitivity to the treatment: 5/7 pts who underwent disease regression had an early and transitory increase of the number of CD14/CD86 and CD14/CD163 positive cells, which was absent or negligible in non responder pts.
  • CONCLUSIONS: These data suggest that neoadjuvant CT-RT modulates the cellular components of innate immune responses, that could represent valuable predictive factors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Gandola L, Nantron M, Marchianò A, Pession A, Indolfi P, Di Cataldo A, Collini P, Arcamone G, Fossati Bellani F, Spreafico F: Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials. J Clin Oncol; 2009 May 20;27(15_suppl):10031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials.
  • : 10031 Background: Children with metastases at diagnosis for Wilms tumor (WT) still display a worse prognosis compared to localized disease.
  • METHODS: We analyzed survival results in patients with stage IV WT enrolled in the AIEOP CNR92 and TW2003 clinical trials (3/1992-3/2008).
  • Treatment strategy across these trials evolved in terms of sparing whole lung radiotherapy (RT) in case of complete disappearance of lung metastases after primary chemotherapy and a doxorubicin cumulative dose reduction from 360 mg/m<sup>2</sup> to 240 mg/m<sup>2</sup> in TW2003.
  • RESULTS: Of 553 in-study patients aged less than 18 years, 68 (12%) were classified as stage IV (38 patients in CNR92, 30 in TW2003; median age 58 months).
  • Adjuvant therapy included 8-month 3-drug chemotherapy for non anaplastic "local" tumor stage I to III (flank RT for stage III), or an intensified regimen for anaplastic histology, adding etoposide, carboplatinum and ifosfamide (6 patients).
  • Overall 19 tumor failure occurred (3 in anaplastic tumors): metastases progression 9, abdominal relapse 5 (combined to liver and mediastinum in 1 case each), lung 4, liver 1.
  • Overall, RFS was 86% in patients who achieved a complete metastases remission (in 2 cases by surgery) compared to 55% in patients who did not (Logrank p<.05).
  • Noteworthy the omission of lung RT in TW2003 trial for complete responders evaluated at week 6 did not jeopardize survival (85% RFS, vs 58% for those children with persistence of metastases and lung RT).
  • The impact of metastatic tumor burden deserves further analysis.
  • Withholding RT in rapidly complete responders patients did not compromise outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Arafat W, Abdelghany A, Awad N: A clinical trial to study the effect of adding cis-retinoic acid during and after conventional treatment for pediatric neuroblastoma patient. J Clin Oncol; 2009 May 20;27(15_suppl):10057

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10057 Background: Neuroblastoma is predominantly a tumor of early childhood, with two thirds of the cases presenting in children younger than 5 years.
  • Patients who received cis-retinoic acid had significantly better 3-year event-free survival than patients receiving no maintenance therapy.
  • The aim of this study is to evaluate the efficacy of cis-retinoic acid when used in combination with conventional chemotherapy in pediatric patient who is newly diagnosed with locally advanced neuroblastoma.
  • METHODS: Seventeen newly diagnosed children with locally advanced neuroblastoma who is candidate to receive chemotherapy were also received cis-retinoic acid starting at a dose of 160 /m<sup>2</sup> day (day 2-15 of chemotherapy) first the 3 patients, 20% dose reduction were allowed if toxicity occurred in first cohort of patient. . Patients were giving the drugs for at least 4 cycles.
  • RT-PCR analysis of several related genes was done from tumor, sample after treatment.
  • Patients were stage III, IV (70%), II (30%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962453.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Chlebowski RT, Schwartz A, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Chien JW, Chen C, Wactawski-Wende J, Gass M, Women's Health Initiative Investigators: Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial. J Clin Oncol; 2009 May 20;27(15_suppl):CRA1500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial.
  • : CRA1500 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962442.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Merrell RT, Lachance DH, Anderson SK: Seizures in patients with glioma treated with phenytoin and levetiracetam. J Clin Oncol; 2009 May 20;27(15_suppl):e13020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seizure outcomes were measured by time to second seizure and seizure frequency.
  • 64% had grade 4 astrocytoma.
  • There was no difference in seizure outcome between the phenytoin and levetiracetam groups when comparing time to second seizure (p = 0.584), second seizure rates (p = 0.462), and average seizures per month (p = 0.776).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962817.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Overgaard J Sr, Hoff CM, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Johansen J, Andersen LJ, Evensen JF, Danish Head and Neck Cancer Group (DAHANCA): Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 trial. J Clin Oncol; 2009 May 20;27(15_suppl):6007

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 trial.
  • : 6007 Background: The study aimed to evaluate if correction of low hemoglobin (Hb) levels by means of the erythropoietin stimulating agent: darbepoetin alpha (Aranesp) during radiotherapy (RT) improves outcome in patients with HNSCC.
  • METHODS: Pts with HNSCC eligible for primary RT alone and with Hb values below 14.0 g/dl were randomized to receive Aranesp together with accelerated fractionated RT. Pts. were stratified according to gender, T and N staging, tumor site, and institution.
  • Aranesp was given subcutaneously in a dose of 150 micrograms weekly during RT, or stopped earlier if the Hb exceeded 15.5 g/dl.
  • RESULTS: In total, 522 patients (of a planned intake of 600) were included at the time of the interim analysis.
  • Among these, 201 developed a loco-regional failure (primary endpoint).
  • The patients were evenly distributed according to the stratification parameters (gender, T and N staging, tumor site, institution).Aranesp resulted in the expected increase in Hb in more than 81% of the patients.
  • CONCLUSIONS: Correction of the Hb level with Aranesp in patients with HNSCC resulted in a significantly poorer tumor control after radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962413.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Herndon JE 2nd, Kirkpatrick J, Gururangan S, Bailey L, Friedman AH, Friedman HS: Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):2015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM).
  • : 2015 Background: Standard GBM treatment includes TMZ and RT, and results in a median progression-free survival and median survival of 6.9 and 15.8 months, respectively.
  • GBM have high concentrations of vascular endothelial growth factor (VEGF), higher levels are associated with poorer prognosis.
  • This study aims to improve the survival of newly diagnosed GBM patients by incorporating an anti-angiogenic agent with RT and TMZ, and adding a topoisomerase I inhibitor, and an anti-angiogenic agent to TMZ post-RT therapy.
  • METHODS: Patients received standard RT and TMZ at 75 mg/m<sup>2</sup>/day, with BV at 10 mg/kg every 14 days beginning a minimum of 28 days post-operatively.
  • Following the completion of RT, patients received 6 cycles of BV, TMZ and CPT-11.
  • All the patients have completed RT; 40 patients continue to receive BV, TMZ, and CPT-11.
  • Twenty-two patients have completed 6 cycles of BV, TMZ, and CPT-11; 17 of them had a cold PET One patient developed a CNS hemorrhage (grade 2) necessitating stopping BV.
  • Five patients developed thrombocytopenia for which TMZ was held (grade 3, n = 1; grade 4, n = 4).
  • There were no other ≥ grade 3 toxicities, including no wound dehiscence during RT.
  • Twelve patients had tumor progression, and 14 stopped because of toxicity, including: 6 with fatigue; 3 with PEs; 2 with grade 4 thrombocytopenia; the patient with CNS hemorrhage, and one each with a rectal abscess and sepsis.
  • There have been 7 deaths: 5 from tumor progression; one each from sepsis and PEs.
  • CONCLUSIONS: Adding BV to TMZ and RT followed by BV, TMZ with CPT-11 is tolerable and efficacious.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964581.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Sharma D, Knight BB, Yacoub R, Liu T, Taliaferro-Smith L, Nagalingam A, O'Regan RM: Using epigenetic reprogramming to target triple-negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e14565

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since all endocrine therapies are designed to block ER function in some way, the identification of new therapies or strategies that could sensitize TN breast cancers to existing endocrine therapy could provide a revolutionary means of treating this aggressive subtype of cancer Methods: We examined the efficacy of combined treatment of HDAC inhibitor LBH589 and DNMT inhibitor decitabine to regenerate ER and PR in TN breast cancer cells using RT-PCR and immunoblotting.
  • Tumors biopsies were analyzed for ER and PR re-expression by western blot analysis and immunohistochemistry at the end of the treatment.
  • CONCLUSIONS: The importance of epigenetic events such as DNA methylation and HDAC inhibition in tumor progression is becoming increasingly evident.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963687.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Quesenberry PJ, Del Tatto M, Berz D, Miner T, Ng T, Winer ES, Aliotta J, Colvin G, Dooner M, Dooner G, Fontaine JP: Marrow cell genetic phenotype change induced by human lung cancer cells. J Clin Oncol; 2009 May 20;27(15_suppl):11108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minced tumor tissue at 50-100 mg was co-cultured in a semi-permeable culture plate insert opposite 3.0 ×10<sup>6</sup> human marrow cells.
  • Marrow cell RNA was analyzed for lung specific mRNA using real time RT-PCR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963460.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Park K, Ahn Y, Chen M, Cho E, Kim J, Min Y, Kim H, Zhu G, Heo DS, Wu Y: A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN): Interim analysis. J Clin Oncol; 2009 May 20;27(15_suppl):7538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CCRT with D (20 mg/m<sup>2</sup>) and P (20 mg/m<sup>2</sup>) was administered every week for 6 weeks with a total dose of 66 Gy of thoracic RT as 33 fractions.
  • The primary endpoint is time to progression (TTP).
  • Total target number of patients is 458.
  • Grade 3-4 neutropenia occurred in 5.4% of 203 consolidation cycles.
  • At the time of this analysis, there were 40 and 41 deaths in the observation and consolidation arms, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963307.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Goldkorn A, Xu T: Targeting prostate cancer progenitor cells with telomerase interference: A novel therapeutic strategy. J Clin Oncol; 2009 May 20;27(15_suppl):e22029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e22029 Background: We investigated whether telomerase, which is critical for benign stem cell activation, also plays a role in prostate cancer progenitor cells (PCPCs), which are thought to mediate therapy resistance and cancer progression, and we tested whether telomerase interference can effectively inhibit PCPC proliferation.
  • PCPCs were characterized for gene expression (RT-PCR), clonogenicity (colony formation), invasiveness (matrigel chamber), and telomerase activity (qPCR-TRAP).
  • RESULTS: An integrin α<sub>2</sub>β<sub>1</sub><sup>+</sup>CD<sub>44</sub><sup>+</sup> putative PCPC population was isolated from 6 human prostate tumors.
  • CONCLUSIONS: We have shown that human prostate tumors contain a subpopulation of prostate cancer progenitor cells (PCPCs) marked by an undifferentiated gene expression profile, vigorous clonogenicity and invasiveness, and high levels of telomerase activity that can be successfully exploited to neutralize these cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963140.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Power DG, Jhawer M, Feilchenfeldt JW, Kelsen DP, Shah MA: Metastatic gastroesophageal cancer and long-term survival. J Clin Oncol; 2009 May 20;27(15_suppl):4560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4560 Background: Despite modest therapeutic improvements, resistance to systemic chemotherapy develops in most pts with advanced gastric/GEJ (GE) adenocarcinoma.
  • We describe clinicopathological characteristics of a large cohort of long term survivors(LTS) with metastatic GE adenocarcinoma.
  • METHODS: Our institutional database of pts with GE adenocarcinoma who received chemotherapy between 1999-2008 identified 103 pts with metastatic disease (M1) surviving >2 years from M1.
  • From the time of M1, 103 pts (9%) lived >2 yrs.
  • Tumors were located at GEJ/cardia (n=52), body/fundus (n=29), antrum/pylorus (n=22), and were mainly poorly differentiated (n=61).
  • Surgery was performed in 28 pts, 26 gastrectomies (15 with occult peritoneal M1, 11 once peritoneal M1 cleared) and 2 metastatectomies; 7 pts received RT(6 to primary, 1 to M1 site).
  • We are now exploring tumor and normal tissue from LTS versus matched controls (survival <1 year) for molecular/genomic correlates for LTS No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963060.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Fernandez-Martos C, Aparicio J, Salud A, Alonso V, Massuti B, Safont M, Vera R, Escudero P, Maurel J, Pericay C: Multicenter randomized phase II study of chemoradiation (CRT) followed by surgery (S) and chemotherapy (CT) versus induction CT followed by CRT and S in high-risk rectal cancer: GCR-3 final efficacy and safety results. J Clin Oncol; 2009 May 20;27(15_suppl):4103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible pts had medium or distal high risk RC defined by MRI and/or US: Tumors within 2mm of mesorectal fascia, distal T3 at/below levators, resectable T4 and T3N+.
  • Pts, stratified by center, were randomized assigned to receive either Arm A : capecitabine (Cap) 825 mg/m2 BID 5 d/w, oxaliplatin (Ox) 50 mg/m2 IV weekly x 5 and concomitant RT: 50.4 Gy in 28 fractions.
  • Primary endpoint: pathological complete response (pCR).
  • During treatment period 6 pts died A/B: 2 vascular, 1 suicide/ 3 post-op.
  • Pts with any grade ¾ toxicity during CRT were arm A/B: 29% (14/49) and 23% (12/53).
  • Any grade ¾ toxicity during adjuvant/induction CT were 51% (19/37) and 17% (9/54); χ<sup>2</sup>,p= 0.0004.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961193.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Reuben JM, Lee B, Lucci A, Gao H, Cohen EN, Li C, Krishnamurthy S, Hortobagyi GN, Woodward WA, Cristofanilli M: Disseminated tumor cells in primary breast cancer: Evaluation of the percentage of breast cancer stem cells in bone marrow aspirates of patients receiving neoadjuvant chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated tumor cells in primary breast cancer: Evaluation of the percentage of breast cancer stem cells in bone marrow aspirates of patients receiving neoadjuvant chemotherapy.
  • : 505 Background: Disseminated tumor cells (DTC) in the bone marrow (BM) are related to poor prognosis of primary breast cancer (PBC).
  • METHODS: BM was collected from 90 PBC patients at time of surgery to assess DTC (CD326<sup>+</sup>CD45<sup>-</sup>) and CSC (CD326<sup>+</sup>CD45<sup>-</sup>CD44<sup>+</sup>CD24<sup>-</sup>) by FACS analysis.
  • RNA extracted from 61 BMC was analyzed for Notch-1, ER, and HER-2 transcripts by RT-PCR; the level of each transcript was normalized to that of the housekeeping gene, GAPDH.
  • A total of 29 patients (32%) received neoadjuvant chemotherapy, including 8 patients with anti-HER-2 targeted therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960787.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Cai X, Shedden K, Ao X, Lawrence TS, Lubman DM, Kong F: Comparative proteomic analysis of radiation induced changes in non small cell lung cancer patients with or without radiation induced lung toxicity. J Clin Oncol; 2009 May 20;27(15_suppl):e22146

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 20 Patients with NSCLC in 3 stage- matched groups and treated with radiation therapy (RT) or chemoradiation were included in this analysis: 6 grade 0 (group 0), 8 grade 1 (group 1), and 6 grade ≥ 2 RILT (group 2).
  • Platelet poor plasma was obtained pre-RT, at 2-, 4-, 6-week during-RT, and 1-, 3-month post-RT.
  • ANOVA model was applied for significance test.
  • At baseline (Pre-RT), the levels of Vitronectin and C4-A in group 2 were both significantly higher than that in group 0 (p=0.008 and 0.021, respectively).
  • At 2-week during RT, the levels of Ceruloplasmin, Prothrombin and β2GP1 in group 1 were significantly higher than that in group 0 (p=0.017, 0.011 and 0.013, respectively).
  • At 4-week during RT, the levels of β2GP1 in group 1 and group 2 were significantly higher than that in group 0 (p=0.005 and 0.014).
  • At 6-weeks during RT, Prothrombin, C3, Complement factor H, C7 and Complement factor I also had some significant changes among three groups.
  • CONCLUSIONS: Plasma proteins related to inflammation, coagulation and fibrosis, such as β2GP1, change differently during RT in patients with and without RILT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963529.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Hameed S, Jamshed A, Hussain R, Ali M, Iqbal H, Majeed U, Shah MA: Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors. J Clin Oncol; 2009 May 20;27(15_suppl):6055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors.
  • : 6055 Background: The treatment of locally advanced nasal and paranasal sinus tumors is controversial.
  • Our aim was to determine survival in patients with locally advanced nasal and paranasal sinus tumors treated with neoadjuvant chemotherapy followed by radiotherapy or chemoradiation (RT/CRT).
  • METHODS: Between August 2005 and August 2008, 21 patients with AJCC stage III or IV nasal and paranasal sinus tumors were treated with neoadjuvant chemotherapy followed by RT/CRT in our institution.
  • Following RT/CRT 86% (18/21) had complete regression of disease.
  • CONCLUSIONS: Gemcitabine cisplatin chemotherapy has good activity in nasal and paranasal sinus tumors.
  • In combination with RT/CRT survival rates are encouraging and the approach merits further investigations in clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961932.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results.
  • : e14527 Background: Preclinical studies demonstrate synergistic anti-tumor activity with the combination of E + C.
  • METHODS: Patients received E per oral for days 1-21 of a 28 day cycle.
  • RESULTS: 24 patients enrolled: 13 M, 11F; median age 62 (32-77); median number of prior cytotoxic chemotherapy regimens 1 (0-3; 75% with prior RT).
  • At DL2, one patient experienced grade 3 small bowel obstruction of uncertain etiology, and the dose level was expanded to 6 evaluable patients without additional DLT.
  • Adverse events per cycle (total n = 63 cycles; 20 patients evaluable for toxicity) include: lymphopenia G3 (19%), AST G3 (3.2%), alkaline phosphatase G3 (3.2%), ALT G3 (1.6%), hyponatremia (1.6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Yuan S, Frey KA, Gross MD, Ramnath N, Ten Haken RK, Cai X, Hayman JA, Kong F, University of Michigan Medical School Departments of Radiation Oncology and Radiology: Pulmonary functional map on V/Q SPECT and TGFβ1 during radiotherapy and post-treatment lung function in patients with non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):7543

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, ventilation (V) is also important, while the change of V/Q SPECT map and TGFβ1 during radiotherapy (RT) maybe more predictive for the lung function post-treatment.
  • METHODS: Patients with stage I-III NSCLC undergoing radiation based treatment were included and V/Q SPECT-CT, circulating TGF ß1 and carbon monoxide diffusing capacity (DLCO), as the key parameter of pulmonary function test, were assessed pre-, during- and 3 months post-RT.
  • RESULTS: Total 45 patients with stage I-III NSCLC undergoing radiation (>60 Gy) were enrolled.
  • All patients had functional defects (V, or Q or both) at or adjacent to the tumor and the V/Q defects were mismatched in 40%, 50% and 23% patients, pre-, during- and post-RT, respectively.
  • After 45 Gy, the V and Q defects improved remarkably in 38.4% and 34.6% patients respectively, and the V scores were also improved significant during-RT (p<0.01).
  • The Q scores of ipsilateral lung and V score of both lungs during-RT were correlated with DLCO 3 months post-RT margin-significantly (p=0.07) and significantly (p=0.02).
  • The TGFß1 level decreased significantly during-RT and TGFß1 ratios (over the pre-RT level) at 4- and 6-week during-RT correlated with DLCO 3 months post-RT significantly (p=0.05).
  • CONCLUSIONS: The V/Q SPECT map and TGFß1 level change during RT, and these changes are predictive for the lung function post-treatment in patients with NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963319.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Specenier PM, Lalami Y, Vermorken J, Lacombe D, El-Hariry I, Bogaerts J, Awada A: EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC). J Clin Oncol; 2009 May 20;27(15_suppl):6017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC).
  • METHODS: Eligible tumors were SCCHN: T3-T4 larynx (Lx), T2-T4 hypopharynx (Hx) N0-3 M0.
  • The objective of this trial is to determine MTD, DLT and recommended dose of LAP when administered with TPF IC (docetaxel (T) 75mg/m2 (60 mg/m2 for the first cycle) d1, CDDP 75mg/m2 d1, 5FU 750mg/m2/d continuous infusion d1-d5 q3weeks) followed by CRT (weekly carboplatin AUC 1.5 and RT 70Gy in 7 weeks; 2Gy/fx).
  • RESULTS: Seven male patients were included; tumor sites: LX (n = 3) / Hx: (n = 4), median age 59 years (range: 47-79), WHO PS 0-1, no severe or uncontrolled comorbidity.
  • Renal toxicity was observed among these 3 pts (grade 4 [n = 1], grade 2 [n=1] and grade 1 [n=1]), with 1 DLT, leading to treatment interruption in this group.
  • As LAP plus cisplatinum plus RT was feasible in another study, a second cohort was conducted in 4 pts, receiving LAP at the same dosage, and docetaxel (T) was only introduced from cycle 2 of IC to see what is the role of T in the observed side effect.
  • Two DLTs were observed among this second cohort of subjects: one pt presented a grade 2 renal toxicity, grade 3 diarrhea and dehydration and a second pt presented a grade 3 anorexia and grade 3 stomatitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962424.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Lu C, Stewart DJ, Ji L, Ramesh R, Jayachandran G, Erasmus J Jr, Lee JJ, Templeton NS, McMannis JD, Roth JA: A phase I trial of intravenous therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e19065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of intravenous therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer.
  • : e19065 Background: The tumor suppressor gene FUS1 is frequently inactivated early in lung cancer development.
  • To date 23 patients have been entered on study at 6 dose levels, with 21 patients currently evaluable for the primary endpoint of cycle 1 toxicity.
  • Among 4 patients treated without premedications, all 4 developed grade 2 or higher fevers within 24 hours of treatment.
  • Among the 17 patients premedicated with dexamethasone and diphenhydramine, 4 developed grade 1 fever.
  • There have been no other grade 2 or higher drug-related toxicities.
  • Median survival time for all patients is 10.3 months.
  • Pre and 24 hour posttreatment tumor biopsies were obtained from 4 patients.
  • A quantitative real time reverse transcriptase PCR (RT-PCR) analysis using a plasmid FUS1 sequence-specific probe have been performed on 3 paired-samples blinded to time of biopsy.
  • A high level of plasmid FUS1 expression was detected in all 3 posttreatment samples but not in three pretreatment samples and negative controls by RT-PCR.
  • CONCLUSIONS: DOTAP:cholesterol FUS1 nanoparticles can be safely administered intravenously in lung cancer patients with demonstrable gene expression in posttreatement tumor biopsies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962142.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Blaszkowsky LS, Hong TS, Zhu AX, Kwak EL, Mamon HJ, Shellito PC, Cusack JC, Berger D, Horgan K, Ryan DP: A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer (LARC). J Clin Oncol; 2009 May 20;27(15_suppl):4106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer (LARC).
  • Beva, a vascular endothelial growth factor (VEGF) inhibitor with demonstrated activity in colorectal cancer, and erl, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor may both serve as radiation sensitizers.
  • The primary endpoints were determination of the maximally tolerated dose (MTD) and pathologic complete response (pCR).
  • A total of 25 pts will be treated at the MTD.
  • At a median follow-up of 7 months, there have been no local recurrences in patients who completed study therapy.
  • Grade 3-4 treatment related TOX included: lymphopenia 6 (59%), diarrhea 4 (24%), rash 2(12%), cardiac ischemia 1(6%), transaminitis 1(6%), mucositis 1(6%).
  • CONCLUSIONS: Beva and erl in combination with infusional 5-FU and RT appears to be a highly active preoperative regimen for locally advanced rectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961180.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Arenas Prat M, Rovirosa A, Sabater S, Ameijide A, Henríquez I, Servitja S, Cabezas I, Mur E, Gumà J: Experience with endometrial carcinoma (EC): A population-based study in Tarragona Province (Spain). J Clin Oncol; 2009 May 20;27(15_suppl):e16550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16550 Background: To evaluate outcome, failure patterns, prognostic factors and radiotherapy (RT) toxicity after postoperative RT for EC in Tarragona Province (Spain).
  • METHODS: A retrospective population-based review on 232 patients (pts) between 1997 and 2000 from different gynaecological Dpt. and in a single oncologist institution with RT Units.
  • Multivariate analysis of disease-free survival (DFS), overall survival (OS), adjuvant RT, RT toxicity (RTOG), prognostic factors for survival, and the distance in Km to the RT Units.
  • Distance to RT Units >70 Km in 15% pts.
  • Grade (G): 35.7% G1, 45.3% G2, 19% G3; miometrial invasion: 44.1% >50%, 46% <50%, 9.9% not invasion.
  • 2) RT in 73.5%: 47% external beam radiotherapy (EBI) and brachytherapy (BT), 9.4% BT alone, 17.1% EBI alone.
  • Grade 3 and 4 toxicity: 12 (9%) pts, 6 early and 6 late.
  • Relapses: 26/232 (11.6%), S-I: 11/26 (42%), S-II: 1/26 (3.8%), S-III: 5/26 (19.2%), S-IV: 3/26 (11.5%).
  • Multivariate analysis: significant prognostic factors for poor outcome were age (p < 0.01), lymph nodes dissection (p < 0.001), pathologic subtype (p < 0.001), grade of differentiation (p < 0.001), and deep myometrial invasion (p < 0.005).
  • CONCLUSIONS: Survivals, RT toxicity and relapse sites were similar to the other reported series.
  • Predictors of poor outcome were age, lymph nodes dissection, pathology subtype, grade of differentiation, and deep myometrial invasion.
  • Patients of Tarragona Province are in need of a better accessibility to the radiation units.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960813.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Mehta RS, Jackson D, Schubbert T, Hsiang D: HER2 FISH ratio cut-points and pathologic complete response (pCR), residual tumor (RT), HER2 status, and survival prediction in HER2-positive breast cancer (BC). J Clin Oncol; 2009 May 20;27(15_suppl):e22033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HER2 FISH ratio cut-points and pathologic complete response (pCR), residual tumor (RT), HER2 status, and survival prediction in HER2-positive breast cancer (BC).
  • It is known that quantitative HER2-FISH ratio correlates with ER levels and HER2-positivity imparts a higher grade in ER-positive BC.
  • Moreover, HER2 ratio (>4) correlated with higher Ki-67 (r= 0.5, p=0.01) and grade (p trend=0.05) in ER-positive subtype, inferring a biologic cut-point.
  • RESULTS: Of patients with stage I-IV BC treated neoadjuvantly (92% trastuzumab-based), pCR was 0% (0/13) in ER-positive-low-HER2 compared to 77% (10/13, p=0.0001), 75% (24/32, p<0.0001) and 37.5% (3/8, p=0.043) in ER-positive-high-HER2, ER-negative-high-HER2 and ER-negative-low-HER2, respectively.
  • DFS was 100, 90, 80% and 60% (logrank-trend p<0.05) in these 4 subtypes (excluding stage IV), respectively, at a median follow-up of 38 months (range 6-72).
  • In ER-negative subtypes, DFS was 97% and 29% (logrank p=0.0001) in patients with or without pCR; of the six with RT, 0% DFS was noted in four with HER2-negative/HER2-reduced (HER2-R) RT, compared to 100% in the two with unchanged HER2 (p=<0.05, logrank test).
  • In ER-positive subtypes, DFS is 95% overall, and 100% in patients with RT; 7 of 10 tested RT were HER2- R.
  • In hypothesis generating analysis, HER2-R may underlie relapse in ER-negative subtypes (HER2-basal-transitional-residual), while it may be beneficial in ER-positive subtypes (luminal-B- A-transitional) by reducing HER2-pathway mediated endocrine resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963149.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Mahalingam D, Medina E, Swords RT, Kelly KR, Carew JS, Robbert CH, Szegezdi E, Francis GJ, de Jong S, Nawrocki ST: Effect of sunitinib on TRAIL-induced apoptosis in preclinical colon cancer models. J Clin Oncol; 2009 May 20;27(15_suppl):e14633

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14633 Background: Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis, however not all cancers respond to TRAIL, which may be due to activation of survival signals.
  • Sunitinib is a potent inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).
  • These receptors and their signaling cascades promote cell survival and drug resistance.
  • The TRAIL+sunitinib combination significantly reduced tumor burden in both xenograft models compared to either treatment alone.
  • The reduction in tumor volume correlated with increased apoptosis and decreased tumor proliferation and angiogenesis as determined by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay and immunohistochemistry for Proliferating Cell Nuclear Antigen and VEGF.
  • CONCLUSION: These results are the first to demonstrate that simultaneous treatment with TRAIL and sunitinib reduced cell viability, induced apoptosis, inhibited tumor proliferation and angiogenesis in both in vitro and in vivo models of colon cancer, and warrants further investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964192.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Fernandes A, Faerber J, Finlay J, Shen J, Lin L, Evans T, Stevenson J, Langer C, Glatstein E, Hahn S, Rengan R: Clinical outcomes of elective nodal irradiation (ENI) compared with involved field radiotherapy (IFRT) in NSCLC. J Clin Oncol; 2009 May 20;27(15_suppl):7541

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IFRT allows higher radiation doses to the primary tumor with the goal of reducing local failure rates while minimizing toxicity.
  • METHODS: We assessed all patients (pts) with stage III locally advanced or stage IV oligometastatic NSCLC treated with definitive radiotherapy (RT) from January 1, 2003 to August 21, 2008.
  • Involved nodal failures (INF) were defined as radiographic progression in lymph nodes that were initially involved at the time of treatment.
  • RESULTS: A total of 104 consecutive pts (56 ENI vs. 48 IFRT) were assessed.
  • The average RT dose was 6,345 cGy in the ENI group and 6988 cGy in the IFRT group.
  • The median follow-up time was 8.4 mos (0.3-43.4) for all pts and 9.7 mos (1.5-40.1) for survivors.
  • The majority of patients who experienced a local failure also experienced nodal failure, suggesting that local relapse may be linked to subsequent nodal failure.
  • Decreased esophagitis rates in patients treated with IFRT may allow the integration of concurrent, full dose systemic therapy in a greater proportion of patients, as well as higher RT doses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Neyns B, Chaskis C, Dujardin M, Everaert H, Sadones J, Nupponen NN, Michotte A: Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma. J Clin Oncol; 2009 May 20;27(15_suppl):2038

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma.
  • : 2038 Background: High-grade gliomas (HGG) are characterized by neo-angiogenesis.
  • Uptake of fluorinated fenyl-methyl-alanine within the CNS was assessed by PET at baseline and reassessed in responding pts.
  • All pts had PD following surgery, RT and TMZ.
  • A total of 142 treatment weeks (range 2-84) were evaluated; 81% of the administrations were at the 37,5 mg-, 19% at the 25 mg dose level.
  • Decrease in CBV<sub>LTN</sub> and CBF<sub>LTN</sub> was observed in 6/14 evaluable pts after 4 weeks of sunitinib, 5/19 evaluable pts had SD on T1±Gd after 8 weeks; one pt experienced a marked clinical improvement with a reduction in the tumor metabolism on PET.
  • Characterization of the VEGFR, PDGFR, and Kit gene copy numbers and protein expression in the tumors is ongoing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964622.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Naito S, Eto M, Shinohara N, Tomita Y, Fujisawa M, Namiki M, Nishikido M, Usami M, Tsukamoto T, Akaza H: A phase II study of S-1 for the treatment of cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint was the objective response rate (ORR) as confirmed by an independent reviewer.
  • Formalin fixed paraffin embedded specimens, which had been obtained by radical nephrectomy, were used for mRNA expression assay, performed by RT-PCR method.
  • The most common grade 3-4 adverse events assessed according to the CTCAE v.3.0 included anemia (6.7%), neutropenia (8.9%), anorexia (8.9%), hyperglycemia (6.7%), stomatitis (4.4%), diarrhea (4.4%), and fatigue (4.4%).
  • Measurement of the mRNA level of 5-FU-related enzyme in tumors before treatment may facilitate prediction of the response to S-1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964380.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Axelrod RS, Machtay M, Werner-Wasik M, Anne R, Schlossberg H, Laudadio M, Kotak D: Prospective evaluation of incidence and pattern of nausea in patients receiving combined chemotherapy and radiotherapy (RT) above the diaphragm. J Clin Oncol; 2009 May 20;27(15_suppl):e20676

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective evaluation of incidence and pattern of nausea in patients receiving combined chemotherapy and radiotherapy (RT) above the diaphragm.
  • Prevalence of N, V in patients (pts) receiving daily (5/7) RT with weekly (wkly) doublet chemotherapy is not well studied.
  • METHODS: We used a modified Functional Living Index Emesis (FLIE) (Lindley and Mullin) to study N, V in pts receiving 2 chemotherapy agents with RT for upper aero-digestive malignancies.
  • Exclusion criteria were: other causes of N,V or RT below the diaphragm.
  • Most patients received a total of 5 weekly chemotherapy treatments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961682.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Ionta M, Atzori F, Murgia M, Frau B, Barca M, Coinu A, Trogu A, Eltrudis F, Minerba L, Massidda B: Adding cisplatin to an anthracycline-based primary chemotherapy in triple-negative (TN) and non-triple negative (non-TN) T4 breast cancer patients (pts): Long-term outcomes. J Clin Oncol; 2009 May 20;27(15_suppl):583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adding cisplatin to an anthracycline-based primary chemotherapy in triple-negative (TN) and non-triple negative (non-TN) T4 breast cancer patients (pts): Long-term outcomes.
  • Conversely, there is extensive preclinical work showing that TN tumors are highly sensitive to platinum agents.
  • All pts received CMF, RT and hormone-therapy if indicated as adjuvant setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960694.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Lamar RE, Spigel DR, Burris HA, Markus TM, Kuzur M, Ervin T, Fichtel L, Greco FA, Hainsworth JD: Phase II trial of radiation therapy/temozolomide followed by temozolomide/sorafenib in the first-line treatment of glioblastoma multiforme (GBM). J Clin Oncol; 2009 May 20;27(15_suppl):2018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All pts initially received radiation therapy (total 60 Gy, 2 Gy by single daily fractions) plus temozolomide (75mg/m<sup>2</sup> po daily).
  • Pts were evaluated every 8 weeks during temozolomide/sorafenib therapy, and every 3 months after therapy ended, until tumor progression.
  • Median PFS was the primary endpoint.
  • 39 pts (87%) completed concurrent RT/temozolomide therapy, while 6 pts were removed from treatment (PD 4, toxicity 1, intercurrent event 1).
  • Median PFS for pts who received at least 1 dose of sorafenib is also 6 months.
  • Grade 3/4 toxicity during temozolomide/sorafenib was uncommon; 7 pts (16%) required dose reductions of sorafenib during their treatment course.
  • CONCLUSIONS: The addition of sorafenib to standard treatment with RT/temozolomide is feasible and well tolerated by most pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964580.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Khosravi-Shahi P, Izarzugaza Peron Y, Perez-Manga G: Low pathologic complete response (pCR) rate to neoadjuvant chemotherapy in invasive lobular carcinoma of breast: Analysis of subgroup of four phase II trials. J Clin Oncol; 2009 May 20;27(15_suppl):601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiotherapy (RT) and hormone therapy (Ht) were allowed after surgery.
  • Primary objective of the study was to evaluate pCR rate in this subgroup of ps.
  • RESULTS: A total of 185 ps including in the four trials were evaluated.
  • Sixteen ps had LC (16/185 = 8.65%): median age = 50 y (38-66); premenopausal = 56.2%; left breast = 56.2%; median clinical (c) tumor size = 5 cm (3-6); stage:IIA = 6.7%; IIB = 26.7%; IIIA = 33.3%; IIIB = 33.3%; T:cT3 = 50%; cT4 = 28.6%; cN+ = 71.4% (median pN = 2 [0-32]); grade: G2 = 60%, G3 = 40%; ER+ = 78.6%; PgR+ = 64.3%; HER-2+ = 6.25%; phenotype by IHC: Luminal (HR+/HER-2-) = 75% (12/16); Luminal/HER-2+ (HR+/HER-2+) = 6.25%; triple negative (3/16) = 18.75%; p53+ = 25%; EGFR negative = 90%; median Ki-67 = 20% (5-70); adjuvant trastuzumab (H) = 6.25%; RT = 60%, median dose = 50Gy; Ht = 78.6% (tamoxifen = 55%; AI = 45%); type of PCT: docetaxel (T), capecitabine (X), and H (TXH) = 1p (6.2%); doxorubicin (A), T, and X (ATX) = 5 ps (31.2%); bevacizumab, T, and X (BTX) = 5 ps (31.2%); AT = 5 ps (31.2%); median of 5 cycles (2-6).
  • Primary End-Point: Only 1 p (6.25%) had pCR in breast and nodes, and another p had a pCR only in breast, but not in nodes (pCR in breast = 2/16).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement